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ABSTRACT
Embryoid body (EB) formation is a common first step in many human pluripotent stem cell (hPSC)
differentiation protocols. Previous work suggests that EBs are sensitive to growth factor withdrawal if they
are derived from hPSCs maintained in feeder independent media such as mTeSR1. To promote cell
survival,

EBs generated from mTeSR1-adapted hPSCs are sometimes cultured in a medium that

contains basic fibroblast growth factor (bFGF), a trophic factor often used in hPSC cultures to maintain
self-renewal. This distinguishes feeder independent hPSCs from feeder dependent hPSCs. The purpose
of this study was to characterize the effects of bFGF as well as small molecule inhibitors of GSK3β on the
formation, growth, cell-cell signaling and early fate decisions of human EBs. bFGF or GSK3β inhibitor
treated EBs grew in size and showed evidence of cell proliferation. Control EBs that were fed only a
basal serum free EB medium without added growth factors tended to fall apart in culture, adopted
irregular morphologies and showed no signs of growth or proliferation. Changes in cell-cell adhesion
commonly observed in differentiating hPSCs were apparent in the bFGF and BIO treated EBs, while
untreated control EBs predominantly expressed E-cadherin, a cell-cell adhesion molecule highly
expressed in undifferentiated hPSCs. Expression of pluripotency markers decreased in all EB groups,
regardless of treatment, and increased germ layer marker expression was detected in all groups, with a
particular bias towards neuroectoderm. Our results suggest a role for GSK3β in the development and
survival of EBs derived from feeder independent hPSCs. These results could inform the development of
protocols for the directed differentiation of feeder independent hPSCs using defined media and small
molecules.
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Chapter 1 – LITERATURE REVIEW

1.1 Introduction
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and
human induced pluripotent stem cells (hiPSCs), can proliferate indefinitely in culture and can in principle
1-3

differentiate into any of the more than 200 cell types in the human body . These properties, known
respectively as self-renewal and pluripotency, make hPSCs attractive as potential cell sources for
applications in drug discovery, toxicology, disease modeling and eventually regenerative medicine, and
as such hPSCs have become the subject of intense research focus.
hESCs were first isolated from the inner cell mass of 5-6 day old human blastocysts in 1998.
Since the immunosurgery technique used to derive a hESC line renders the embryo nonviable, there is a
tremendous ethical controversy surrounding the use of hESCs for research or in the clinic. As a result of
these ethical concerns, federal funding for hESC research in the United States has been limited to just a
few approved hESC lines.
In 2007, hiPSCs were generated from human fibroblasts by retroviral induction of just four
transcription factors: Oct4, Sox2, Klf4 and C-myc. Since then numerous methods for the induction of
pluripotency in human somatic cell types have been developed, including retroviral, lentiviral or adenoviral
induction of different combinations of transcription factors, non-integrating episomal vectors, transposon
vectors, and delivery of synthetic RNA molecules

4-9

. hiPSCs are phenotypically and functionally similar
10

to hESCs, and they are promising cell lines for both research and clinical applications . Patient specific
hiPSCs may be generated and subsequently used for disease modeling or cell therapies, and these
hiPSC derived cells might carry less risk for immune rejection than an equivalent hESC derived
transplant, though this point is controversial

11

.

Examples of cell therapies utilizing hPSC derived cells include dopaminergic neurons to treat
Parkinson’s disease, glial precursors to treat spinal cord injury, pancreatic β-cells to treat type I diabetes,
and cardiomyocytes to treat congestive heart failure to name just a few

12-15

. The strategies devised for

the implementation of these therapies are similar in that they each involve the replacement of a single cell
1

type that has lost function. Current methods for generating these replacement cell types are similar as
well. hPSCs are expanded and then induced to differentiate into the desired cell type (e.g. dopaminergic
neuron or progenitor cell) in vitro, often employing growth factors or small molecules that activate
signaling pathways known to be involved in early embryological development.

The target cell types are

purified, and in some cases they are expanded and allowed to mature before transplantation into the
patient. To date, only three Phase I/II clinical trials involving hPSC derived cells have been conducted or
begun in the U.S.A. One of these trials—to treat spinal cord injuries with glial precursors derived from
hESCs-- was halted early due to financial concerns, not concerns about safety or efficacy

16

.

The other

two trials—to treat age related macular degeneration and Stargardt's Macular Dystrophy with hESC
derived retinal pigment epithelial cells—are ongoing and have reported some early success

17

. However,

despite rapid progress, most hPSC research is still focused on in vitro studies and non-human animal
models, and the long term safety and efficacy of hPSC derived cell therapies is not yet established
hPSCs might find more immediate use in drug discovery

15

.

18, 19

. Many drug candidates that are

effective in murine models of disease are not effective in humans, so it would be advantageous to
develop reliable human preclinical models to assess the efficacy and toxicity of candidate drug molecules
before too many resources are committed to their development. hPSCs offer a virtually unlimited supply
of differentiated cell types that are important for drug metabolism or are particularly vulnerable to the
effects of drug toxicity, such hepatic or cardiac cells. hPSCs also provide a useful model for early human
development as well as human disease progression

19

. Numerous hiPSC lines have been generated to

model diseases such as Down syndrome, Fanconi anemia, Huntington’s disease and schizophrenia

20-23

.

1.2 Maintenance of hPSC Self-Renewal
hPSCs are characterized by high expression of transcription factors such as Oct4, Nanog, and
Sox2 as well as membrane antigens SSEA3, SSEA4, Tra-160 and Tra-181

24,25

. Oct4, Nanog, and Sox2

form a regulatory network that maintain self-renewal and pluripotency by co-occupying the promoter
regions of hundreds genes associated with repressing differentiation

26

. They are alkaline phosphatase

positive, grow in compact colonies and have a high nuclear to cytoplasmic ratio.

2

The pathways that contribute to hPSC self-renewal differ somewhat from those involved in murine
PSC (mPSC) self-renewal. For instance, treatment with LIF and BMP4 are known to promote mPSC selfrenewal, while LIF has no effect on hPSC self-renewal and BMP4 actively promotes hPSC differentiation
24

.

Numerous groups have found that hPSC self-renewal depends on basic fibroblast growth factor

(bFGF) as well as Activin A, TGFβ1 and IGF-1

27-29

. These signaling proteins activate intracellular

pathways such as Raf/ERK, PI3K/AKT and SMAD2/3, which in turn regulate the transcriptional circuitry
that maintains self-renewal and pluripotency

30

. Curiously, the requirement of bFGF and Activin A in

hPSC maintenance culture makes hPSCs more similar to post implantation mouse epiblast stem cells
than mPSCs

31

.

Three general methods have been developed for the maintenance and expansion of hPSC
populations in vitro: feeder dependent, feeder free, and feeder independent.
method is the oldest and is still commonly used.

The feeder dependent

hPSC colonies are cocultured with mitotically

inactivated mouse embryonic fibroblasts (MEFs) or in some cases human fibroblast feeders

1, 32

. Typically

the coculture is fed a base medium consisting of DMEM or DMEM/F12 and a commercially available
serum replacement to which a small amount of bFGF is added. bFGF acts on the hPSCs themselves by
activating Erk signaling and the PI3K/Akt pathway, as well as stimulating the MEFs to secrete growth
factors which then stimulate the hPSCs.
These secreted factors include transforming growth factor β1 (TGFβ1), Activin A, various
heparan sulfate proteoglycans, and gremlin (an inhibitor of BMP signaling)

33, 34

.

In 2001, Xu et al.

demonstrated that culturing hESCs in a bFGF containing medium that had been conditioned by MEFs
was sufficient to maintain self-renewal

35

. The hESCs were cultured in dishes coated in Matrigel, an

extracellular matrix extract derived from the murine Engelbreth-Swarm tumor that is rich in laminin and
collagen IV

36

. This culture method is sometimes called feeder-free culture.

Though effective and widely used, the feeder dependent and feeder-free culture methods have
significant drawbacks

37

. The feeder dependent method is time and labor intensive, making scale-up of

hPSC cultures difficult. And both the feeder dependent and feeder-free systems rely on factors secreted
by cells of non-human origin (MEFs), complicating the process of FDA approval of cell therapies derived
3

from hPSCs. For example, hESC derived retinal pigment epithelial cells currently being explored as a
treatment for Stargardt’s Macular Dystrophy are classified as a xenotransplant, since the hESCs were
originally cocultured with MEFs

17

. The undefined nature of feeder based culture systems also makes it

difficult to standardize hPSC protocols and replicate experimental results obtained in different laboratories
37

.
Feeder dependent methods for maintaining hPSCs have led to contamination of those hPSC

lines with non-human molecules. MEF dependent hESCs as well as embryoid bodies (EBs) derived from
38

those hESCs metabolically incorporate a non-human sialic acid, Neu5Gc

.

Many people have

antibodies against Neu5Gc circulating in their blood, and so there is a risk that feeder dependent hPSCderivatives could elicit an immune response upon transplantation into a patient. This could limit the
clinical use of hPSC derived cells.
These difficulties have motivated the development of hPSC culture mediums that do not rely on
MEF coculture or MEF conditioned medium at all.

So-called feeder independent media are

supplemented with growth factors and small molecules found to support hPSC self-renewal in analyses of
MEF conditioned media. Several feeder independent hPSC maintenance media have been developed,
some of which are commercially available.
One of the most popular feeder independent media is mTeSR1

39

.

Compared to MEF

conditioned media, mTeSR1 has a very high concentration of bFGF (100 ng/ml). This high concentration
bFGF was found to suppress BMP signaling
GABA and pipecolic acid

40

. mTeSR1 also contains TGFβ1, lithium chloride (LiCl),

39

. LiCl is a small molecule inhibitor of glycogen synthase kinase 3β (GSK3β),

and it is included in mTeSR1 based on a report by Sato et al. indicating that activation of canonical Wnt
signaling via the chemical inhibition of GSK3β enhances hESC self-renewal

41

. GABA and its cofactor

pipecolic acid are included in mTeSR1 based on the observation that undifferentiated hESCs express the
GABA receptor

42

.

Excluding any one of the 5 pluripotency factors results in a loss of proliferative

capacity or down regulation of one or several markers of pluripotency

4

28

.

mTeSR1 is not free of animal products, nor is the mTeSR1 culture system completely defined.
mTeSR1 contains bovine serum albumin, and it is common for mTeSR1 adapted hPSCs to be cultured
on plates coated with Matrigel. A xeno-free version of mTeSR1, TeSR2 is also available, and some
groups have replaced the Matrigel substrate with human vitronectin, laminin 511 or synthetic peptides
that mimic the binding sites of various extracellular matrix molecules, thereby making it possible to
maintain and expand hPSCs in a completely xeno-free environment

43-45

.

Recently a simplified form of

xeno-free TeSR, called E8, has become commercially available. Unlike TeSR2, E8 does not contain
human albumin, and this omission promises to significantly reduce the costs associated with the use of
defined xeno-free media

46

.

1.3 Similarities and differences between Feeder dependent and feeder independent cultures
In 2010, the International Stem Cell Consortium compared eight feeder independent media and
found that only two, Stempro and mTeSR1, were able to support the undifferentiated growth of hESCs for
47

10 passages . According to Yoon et al., hESCs maintained in mTeSR1 have a global gene expression
48

profile that is similar to feeder dependent hESCs . They readily form teratomas, a standard test of
pluripotency, and some groups report that the directed differentiation efficiencies of mTeSR1 adapted
hPSCs are comparable to feeder dependent/free hPSCs

28, 49

.

Nevertheless, there is accumulating evidence that hPSCs maintained in feeder independent
mediums such as mTeSR1 are not identical to their feeder dependent counterparts. MEF dependent and
mTeSR1 adapted hESCs have differing FTIR spectra, suggesting differing macromolecular compositions
50

. Specifically mTeSR1 adapted hPSCs have greater amounts of phosphorylated molecules and higher

amino acid concentrations, while MEF dependent hPSCs have higher levels of carbohydrates. These
differing compositions remain even after the hPSCs are induced to differentiate into mesoderm. The
authors speculated that differences in endogenous production of growth factors or epigenetic changes in
the hPSCs may account for their observations.
Tompkins et al. found that mTeSR1 adapted hPSCs accumulate numerous transcriptional and
51

epigenetic changes that do not go away upon conversion to feeder dependent culture . Blauwkamp et al.
reported that hESCs cultured in mTeSR1 rapidly differentiate in response to exogenous Wnt3a, while
5

canonical Wnt signaling promotes the expansion of undifferentiated MEF dependent hESCs

52

. The

authors linked this difference in the effects of growth factor stimulation to the presence of
lysophosphatidic acid (LPA) in the knock out serum replacement fed to the MEF dependent hESCs. LPA
is not a component of mTeSR1. However, when LPA was added to mTeSR1, the feeder independent
hPSCs responded to Wnt signaling in much the same way as MEF dependent cultures, thus
demonstrating the influence of medium composition on hPSCs' response to exogenous growth factors.
Another group has reported that hPSC maintenance culture conditions affect the efficiency of
differentiation to cardiac lineages

53

. mTeSR1 adapted hESCs yielded significantly fewer cardiomyocytes

than feeder dependent cultures. The authors also noted that mTeSR1 adapted hESCs expressed the
neuroectoderm marker NCAM1 even when undifferentiated, suggesting that prolonged culture in
mTeSR1 might partially neuralize hPSCs.
1.4 Embryoid Bodies
Differences between feeder dependent and mTeSR1 adapted hPSCs are also apparent in some
of the protocols developed for the formation of embryoid bodies (EBs). EBs are multicellular aggregates
that spontaneously form when hPSC colonies are removed from adherent conditions and cultured in
suspension. Cells within the EBs differentiate into cell types from all three germ layers, and so, along with
teratoma formation, the ability to form EBs constitutes a functional test of pluripotency.
54

To a certain extent, EBs recapitulate the development of early embryos . Unlike EBs generated
from embryonic carcinomas, EBs derived from mPSCs and hPSCs display a remarkable degree of selforganization

55, 56

. As mPSCs within the aggregates begin to differentiate, pluripotency markers such as

Oct4 and Nanog are transcriptionally down-regulated. Cells near the outside surface of the EB give rise
to primitive endoderm, which further differentiates into visceral and parietal endoderm

57

.

This

extraembryonic endoderm secretes a basement membrane rich in laminin and collagen IV that separates
the outer endoderm layer from an inner pluripotent epiblast layer (Fig. 1.1)

56, 58

. After a few days in
59

culture, EBs develop a shell of collagen I, reducing nutrient diffusion into the EBs’ interior . In extended
culture, cells in the center of EBs tend to commit apoptosis, and the EBs become hollow in a process
called cavitation. It is believed that cavitation occurs as a result of epiblast cells losing contact with the
6

basement membrane as well as decreased nutrient and oxygen diffusion into the EBs' interior as they
grow in size

60,61

.

Decreased soluble factor diffusion to the center of an EB also creates an interior

signaling gradient, which allows for the emergence of numerous cell types within a single EB. The
heterogenous nature of EB culture can present difficulties for hPSC directed differentiation protocols,
where generating a pure population of differentiated cell types at high efficiency is desired.

Figure 1.1. Cross-section of an embryoid body (EB).
Nonetheless EB formation is a common first step in many protocols for directing the differentiation
of hPSCs. The EB model provides a biomimetic, three-dimensional environment that allows for complex
cell-cell interactions that are difficult to achieve in monolayer cultures, and unlike many monolayer
differentiation protocols, EB culture is compatible with some of the scale-up strategies that have already
been developed for hPSC differentiation, such as stirred tank bioreactors and orbital shakers

62

.

EBs are often fed with growth factors and small molecules in order to drive their specification
towards a particular cell lineage. Methods of producing EBs in the presence of polymers which release
soluble factors from within the EBs in a time controlled manner have been developed in order to reduce
signaling gradients within EBs and promote more homogenous differentiation

63

.

Also it has been

observed that the size of an EB influences the lineage choices of the cells within the EBs. Methods for
7

producing size controlled human EBs from single cell suspensions using forced aggregation in nonadherent 96 well plates or microwells have recently been developed, promising to increase the efficiency
of EB based protocols

56, 64

.

EB formation is often an intermediary step in an hPSC differentiation protocol, and the length of
time the EBs are kept in suspension varies depending on the desired cell type. Cardiomyocyte and
neural progenitor differentiation protocols often begin with an initial period of EB suspension culture
followed by 2D monolayer culture, while many protocols for the generation of hematopoietic progenitors
call for at least two weeks in suspension
desired

65, 66

.

EBs may be grown in suspension for many weeks if

67

.

Traditionally when starting from feeder dependent hPSCs, bFGF is withdrawn from the culture
medium upon EB formation

68

.

In mTeSR1 adapted cultures, on the other hand, growing EBs in a

serum-free medium without bFGF has been more difficult. This difficulty has motivated some research
groups to abandon the EB method in favor of monolayer based differentiation protocols

69

. Antonchuk et

al have previously reported that bFGF treatment of spin EBs generated from mTeSR1 adapted hPSCs
70, 71

.

greatly improves EB survival (personal correspondence)

Similar observations have been reported

in mTeSR1 adapted EBs generated from cell clumps rather than single cells (personal correspondence)
72

.

1.5 FGF signaling in early hPSC differentiation
bFGF is a trophic factor known to promote survival and proliferation in numerous cell types

73

. In

adherent undifferentiated hPSCs, it prevents anoikis, a form of apoptosis resulting from loss of cell
contact with the extracellular matrix

74

. According to Antonchuk et al., treating EBs with bFGF still allows

for the emergence of cells from all three germ layers

71

. Even so bFGF plays a significant role in the

lineage transitions of hPSCs and perhaps should not be regarded as neutral in terms of lineage
commitment. bFGF is often used to induce neural differentiation in hPSCs

75-77

. Moreover the timing of

FGF signaling during the early stages of differentiation can affect the efficiency of neural specification.
Inhibiting bFGF/Erk during early hESC differentiation produces a larger population of cells expressing the
neural stem cell marker Pax6 than non inhibited controls
8

78

. This suggests that early bFGF treatment

+

might attenuate neural differentiation. However after the Pax6 population emerges, bFGF treatment can
increase CNS neural specification while decreasing PNS specification.

Thus the effects of bFGF

treatment on hPSC neural specification may depend on the differentiated state of the cells when they
receive bFGF treatment.
bFGF can act as a competency factor in mesodermal differentiation. hESCs treated with BMP4
differentiate preferentially toward extraembryonic trophectoderm, but treating the hESCs with both BMP4
and bFGF switches the cells to a mesendodermal fate

79

. Through Mek/Erk signaling, bFGF prolongs

Nanog expression, and it was found that enforced Nanog expression during BMP4 treatment could mimic
the effect of bFGF treatment.
FGF sometimes influences cell fate by engaging in crosstalk with other signaling pathways.
According to Israsena et al., bFGF treatment of neural stem cells (NSCs) induces nuclear localization of
β-catenin and activation of canonical Wnt signaling, which then facilitates NSC proliferation and self
renewal

80

. Crosstalk between FGF and canonical Wnt signaling plays a critical role during gastrulation

81

.

mESCs with a mutant FGFR1 do not generate endoderm or cells that migrate through the primitive
streak. These cells also fail to regulate E-cadherin. It was hypothesized that these high levels of Ecadherin sequestered β-catenin at adherens junctions, leaving it unavailable for participation in canonical
Wnt signaling. Thus FGF signaling affects mesendodermal differentiation indirectly by modulating the
available pool of β-catenin. In undifferentiated hPSCs, stimulation with bFGF is correlated with increased
transient phosphorylation of AKT, Erk and GSK3β as well as activation of a Wnt luciferase reporter

82

.

1.6 The Roles of Canonical Wnt Signaling and GSK3β in Regulating Self-Renewal and Early
Differentiation of hPSCs
The canonical Wnt pathway is one of several signaling pathways thought to dominate early
embryological development

83, 84

. In the absence of Wnt ligands, a destruction complex consisting of

GSK3β, Axin, CK1 and APC cooperates to keep levels of cytoplasmic β-catenin very low.

CK1

phosphorylates β-catenin at Ser45, which enables GSK3β to further phosphorylate β-catenin at Ser37
and Ser33

85

. E3 ubiquitin ligase subunit βTrCP recognizes phosphorylated β-catenin, which is then

quickly degraded

86

. When Wnt ligands bind to the transmembrane receptor Frizzled and its coreceptor
9

LRP 5/6, the intracellular protein Disheveled is activated, inducing the CK1 and GSK3β mediated
phosphorylation of LRP 5/6. This creates a high affinity binding site for Axin at the cell membrane.
Sequestering Axin at the membrane inhibits the formation of the destruction complex, and so the
phosphorylation and degradation of β-catenin does not occur. Stabilized β-catenin may then accumulate
in the cytoplasm and translocate to the nucleus, where it forms a complex with transcription factors
TCF/LEF1 to promote the transcription of numerous Wnt target genes.
Crosstalk between the canonical Wnt pathway and other signaling pathways often occurs through
GSK3β, a ubiquitously expressed serine/threonine kinase. GSK3β is one of two GSK3 isoforms (GSK3α
and GSK3β). These isoforms arise from different genes, but they have 85% homology in their kinase
domain. GSK3β is a hub protein that is involved in numerous pathways and cellular processes, including
glucose metabolism as well as the canonical Wnt, Hedgehog, Notch and Receptor Tyrosine Kinase
pathways

85

.

GSK3β is expressed in all mammalian tissues, with especially high expression in the brain

87

. As

a kinase, it is unusual in that it is very active in unstimulated somatic cells, and it is often through
extracellular signals that its activity is reduced

88

.

For example, stimulating cultured cells with insulin

reduces GSK3β activity by 30-70% within a few minutes

89, 90

.

Insulin signaling activates the PI3K

pathway. AKT, a downstream effector of PI3K, subsequently phosphorylates GSK3β at Ser9, greatly
reducing its activity.

Integrin signaling through integrin linked kinase (ILK), growth factor signaling

through Receptor tyrosine kinases (e.g. FGFR, EGFR, NGFR ect) , Ras and MAPK, and signaling
through PKA can also induce Ser9 phosphorylation of GSK3β

91-94

. Though Ser9 phosphorylation is the

most common or at least best characterized route to GSK3β inactivation, phosphorylation at other
residues, including Thr43 and Ser389 through Erk and p38 MAPK signaling respectively also inhibits
GSK3β activity

95,96

.

Conversely GSK3β activity is increased upon auto-phosporylation

phosphorylation by ZAK1at Tyr216

or

97

.

GSK3β targets dozens of substrates for phosphorylation, often resulting in the inactivation of
those substrates

98

. It plays a well-documented role in apoptosis pathways and cell cycle progression.

Activated GSK3β negatively regulates the activity of prosurvival transcription factors like CREB and HIF-1
10

alpha, and it can form complexes with p53 in the nucleus to promote p53 mediated apoptosis

99, 100

.

Small molecule inhibition of GSK3β promotes the survival of neural precursors and cardiac cells that
have been deprived of serum or trophic factors

85

.

Activated GSK3β phosphorylates the cell cycle

regulator p27kip1, and in this case the phosphorylation results in increased stability of p27kip1,which
then leads to cyclinD1 degradation and G1 cell cycle arrest

101

. Conversely GSK3β inhibition increases

the stability of downstream phosphorylation targets such as c-myc and cyclinD1, promoting cell cycle
progression and proliferation

98

.

Though GSK3β participates in numerous signaling pathways, its involvement in the canonical
Wnt pathway has perhaps received the most attention. The currently accepted model of canonical Wnt
signaling does not explicitly require Ser9 phosphorylation and inactivation of Gsk3β.

Nevertheless,

Gsk3β inhibition by small molecule inhibitors is a commonly used method for activating canonical Wnt
signaling in vitro.

Numerous highly selective small molecule inhibitors of Gsk3β are commercially

available, and their use is often more cost effective than recombinant Wnt proteins

102

.

Gsk3β activity in PSCs appears to be species specific and depends on the differentiated state of
the cell. Phoshoproteomic analysis of hESCs grown in a MEF conditioned medium revealed a high level
of Tyr216 phosphorylation of GSK3β, indicating increased GSK3β activity

103

. Singh et al. reported that

mESCs have a large fraction of inactivated GSK3β, while hESCs show a high level of GSK3β activity

104

.

The authors argue that these differences in GSK3β activity reflect differing pluripotent states across
species. mESCs are described as “naïve”, and the hESCs are described as “primed”. In the mESCs,
reduced GSK3β activity is linked to the PI3K pathway, which promotes Ser9 phosphorylation of GSK3β,
stabilizion of c-myc and Nanog and increased self renewal. On the other hand, in hESCs high GSK3β
activity is linked to the inhibition of Wnt/β-catenin induced differentiation.

When the hESCs were

differentiated for 48 hours as EBs in serum containing medium, Ser9 phosphorylation of GSK3β
increased substantially.
There is a great deal of controversy surrounding the role of canonical Wnt signaling in the
regulation of hPSC self-renewal.

A 2004 study by Sato et al. indicated that hESCs grown in

unconditioned medium maintained high Oct4 expression and undifferentiated colony morphology when
11

they were treated with a GSK3β inhibitor

41

. However more recent studies have cast doubt on those early

results. Davidson et al. , for instance, argue that canonical Wnt signaling promotes differentiation, not
105

self-renewal

.

Similarly, Singh et al. found that GSK3β inhibition of hESCs encouraged

mesendodermal differentiation in monolayer culture in manner that was concentration dependent

106

. The

authors suggested that perhaps some of the confusion surrounding the canonical Wnt pathway’s role in
hPSC self-renewal arises because different research groups are using different concentrations of GSK3β
inhibitors in their studies.

At low doses, the hPSCs remain undifferentiated, but at higher doses,

differentiation occurs. This is in agreement with Davidson, who reported that it took a concentration of 4
μM BIO to activate a Wnt reporter in hESCs
experiments

105

. By contrast, Sato et al. used 2 μM BIO in short-term

41

.

mTeSR1 contains 0.98 mM of the GSK3β inhibitor LiCl, but since very little nuclear localization of
β-catenin is observed in hESCs grown in mTeSR1 under standard conditions, this concentration of LiCl
appears to be too low to induce canonical Wnt signaling

107

. So what is the purpose of partial GSK3β

inhibition if not to induce canonical Wnt signaling? The answer may have to do with the effect of GSK3β
inhibition on the morphology of hPSC colonies grown in feeder free and feeder independent conditions.
Differentiated fibroblastic cells are commonly found at the peripheries of hPSC colonies grown in MEF
conditioned medium

108

. One group found that supplementing feeder free hESCs with 2.5 μM BIO led to

an upregulation of E-cadherin and a decrease in the expression of markers of epithelial to mesenchymal
109

. They observed a concomitant decrease in the number of fibroblastic/mesenchymal

transition (EMT)

cells at the edges of the colony. Hence low concentrations of GSK3β inhibitors may promote epithelial
morphology of hPSC colonies in the context of hPSC maintenance culture.
While the precise role of canonical Wnt signaling in hPSC pluripotency remains unresolved, its
role in early embryonic development and PSC differentiation is well established. In mPSCs and hPSCs,
Wnt/ β-catenin signaling cooperates with the Activin and BMP pathways to induce mesendodermal
differentiation

110

. High concentrations of the GSK3β inhibitor BIO in unconditioned hESC medium induce

Brachyury, an early mesendodermal marker, in hESCs in monolayer culture. Brachyury expression in
early mouse and zebrafish embryos has been linked to canonical Wnt signaling, and Brachyury is a direct

12

target of β-catenin in mESCs

111

. In the absence of Activin/Smad signaling, however, canonical Wnt

signaling promotes neural crest fate

112

lack of mesendodermal differentiation

.

113

When β-catenin is knocked out, mESCs showed a complete
. β-catenin -/- mESCs generate EBs that are smaller than wild

type EBs and present defects in cell-cell adhesion, specifically persistent E-cadherin expression.
1.7 E-Cadherin and Epithelial to Mesenchymal Transitions in hPSC Maintenance and
Differentiation
Undifferentiated hPSCs are largely E-cadherin positive, as are human oocytes and
preimplantation embryos

114-116

. In fact its expression in hPSCs is so pervasive that some researchers

have proposed using it as a marker of pluripotency

114

.

hPSCs have low viability when dissociated into

single cell suspensions, and this sensitivity to dissociation has been linked to loss of E-cadherin
signaling

117,118

.

Intact E-cadherin signaling is also crucial during the initial stages of EB formation and culture.
Incubating floating mESC and hESC aggregates with an anti-E-cadherin antibody prevents EB formation
116

. But as cells within EBs differentiate, the initially very high E-cadherin expression gradually decreases

and in some cases, becomes localized to a squamous epithelial layer located on the outside layers of the
EB

113, 116, 119, 120

.

E-cadherin is coupled to the actin cytoskeleton by a protein complex that includes p120 catenin,
β-catenin and α-catenin

121

. Together these proteins comprise an “adherens junction”. Formation and

turnover of adherens junctions can influence intracellular signaling events

122

. For example, in addition to

participating in the formation of adherens junctions, β-catenin is a crucial effector protein in the canonical
Wnt pathway. Studies of other cell types suggest that the β-catenin found in adherens junctions and the
β-catenin that participates in Wnt signaling come from the same pool

123

. Thus E-cadherin signaling can

sequester β-catenin at the cell membrane, leaving it unavailable to participate in canonical Wnt signaling.
Loss of E-cadherin is characteristic of an epithelial to mesenchymal transition (EMT). In cells
undergoing EMT, transcriptional repressors of E-cadherin repressors like Snail, Slug and Twist are up

13

regulated, resulting in a mesenchymal phenotype, resistance to anoikis, loss of cell polarity and increased
expression of other cell adhesion molecules such as N-cadherin and NCAM1

124

.

EMTs occur several times during embryological development, notably during gastrulation and
neural crest development. The canonical Wnt, TGFβ, FGF and EGF signaling pathways can all induce
EMT

83

.

PSCs in both the mouse and human model show signs of EMT during differentiation, and

differential expression of cell adhesion molecules can mark the appearance of various differentiated
phenotypes

114, 125

. For example, cells in the neural plate arising from embryonic ectoderm down regulate

E-cadherin and express N-Cadherin

126

. N-cadherin is present in in vitro derived neural rosettes as well as

mesendodermal tissues that emerge during gastrulation

127, 128

. NCAM1 is often used as a marker for the
+

-

isolation of hPSC derived neurons, though it is also expressed in a population of NCAM1 / CD326
hPSC derivatives that give rise to mesoderm in vitro

129,130

.

GSK3β has been shown to regulate EMT in some cell types. Activated GSK3β phosporylates
and decreases the half life of Snail, a well known mediator of EMT

131

.

Upon GSK3β inhibition, Snail is

stabilized and binds to the E-cadherin promoter, inhibiting its transcription. One group has found that
GSK3β inhibition results in a transcriptional up regulation of Snail as well as stabilization at the protein
level

132

. Other members of the Snail family of transcription factors like Slug and the Twist family of

transcription factors are also targets of GSK3β phosphorylation and destabilization in drosophila

123,133

.

Interestingly FGF signaling can induce EMT via phosphorylation of GSK3β at Ser9 through PI3K/AKT,
and the inactivation of GSK3β can lead directly to stabilization of Snail

14

134

.

Figure 1.2 Cross talk between growth factor, canonical Wnt and cell-cell signaling through GSK3β
and β-catenin.
1.8 Project rationale and hypothesis
It is common to add bFGF to EBs generated from hPSCs adapted to mTeSR1. Given that
GSK3β is a downstream target of growth factor signaling and that Ser9 phosphorylation of GSK3β often
accompanies hPSC differentiation in the EB model, we propose that partial inhibition of GSK3β is
sufficient to promote the survival, growth and early development of EBs. In order to investigate this
hypothesis, we will develop a serum free EB medium that is compatible with mTeSR1adapted hPSCs.
We will generate three groups of EBs in this medium and compare them in terms of growth, survival,
differentiation, proliferation and patterns of cell-cell interactions. The three groups are: a control group of
EBs fed only a basal EB medium, a group supplemented with bFGF, and a group supplemented with a
small molecule inhibitor of GSK3β.
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Chapter 2 – MATERIALS AND METHODS

2.1. hESC culture
H9 human embryonic stem cells (Wicell) were maintained in a mTeSR1 medium (Stem Cell
Technologies) according to the manufacturer’s recommendations. Briefly, H9s (P48-P57) were seeded
onto Matrigel coated (BD Biosciences) tissue culture polystyrene dishes. Medium was exchanged every
day, and cells were passaged every 3-4 days at a split ratio of 1:4 -1:5. Colonies were examined under
an inverted phase contrast microscope for signs of differentiation before passaging, and colonies that
appeared differentiated were removed by scraping with a plastic pipette tip. Cells were passaged using a
combination of enzymatic and mechanical dissociation. Cells were incubated in 1 mg/ml dispase (Stem
cell Technologies 07923) for 7 min or until the edges of the colonies began to curl. The dispase was then
aspirated and the colonies were rinsed three times in DMEM/F12. Enough mTeSR1 to cover the cells
was added, and a glass 5 ml pipette was used to scrape the colonies off the surface of the dish. The
suspension of cell aggregates was transferred to a 15 ml centrifuge tube. The colonies were broken into
smaller pieces by pipetting up and down several times with a 5 ml glass pipette. The appropriate volume
of medium was added, and the cell aggregates were transferred to new Matrigel coated dishes. The
dishes were inspected under an inverted phase contrast microscope to ensure that the aggregates were
the appropriate size (~50-100 μm in diameter). The dishes were placed in a 37° C incubator with 5%
CO2.
2.2 SF- EB medium
A mTeSR1 compatible medium was assembled using the ingredients listed in Table 2.1.
Table 2.1. Formulation of a mTeSR1 compatible EB medium.

Component

1x concentration

Vendor

Catalog Number

DMEM/F12

79.3%

Hyclone

SH30261.01

Bovine Serum Albumin

12.96 mg/ml

Sigma Aldrich

A9418

Insulin

20 μg/ml

Gibco

41400-05

Transferrin

10 μg/ml

Gibco

41400-05

Glutamax

1 mM

Gibco

35050-061
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β-mercaptoethanol

0.1 mM

EMD Millipore

ES-007-E

Non-Essential Amino Acids

1%

Hyclone

SH30238.01

Trace Elements B

0.20%

Cellgro

99-175-C1

Trace Elements C

0.10%

Cellgro

99-176-C1

Chemically Defined Lipids

0.00195 ml/ml

Gibco

11905-031

Na-Selenite

0.0306 μg/ml

Sigma Aldrich

S5261

Reduced Glutathione

1.96 μg/ml

Sigma Aldrich

G4251

Ascorbic Acid

45 μg/ml

Sigma Aldrich

A4544

Thiamine HCl

8.16 μg/ml

Sigma Aldrich

T1270

Sodium bicarbonate

0.544 mg/ml

Sigma Aldrich

S7277

NaCl

1.89 mg/ml

Acros

327300010

2.3 SF-EB Formation Protocol
To form EBs, H9 cells were first cultured in 100 mm dishes (Corning 430167) to 70-90 %
confluence. EBs were formed as described previously with modifications

135

. Briefly, the cells were

incubated at 37° C with 0.5 mg/ml dispase (Stem cell Technologies 07923) in DMEM/F12 for 30-40 min,
or until the colonies began to lift off of the plate. The plates were gently shaken to help dislodge the
colonies. No mechanical scraping was used to dislodge the colonies. The dispase solution was diluted in
DMEM/F12 and the suspension was transferred to a 15 ml centrifuge tube. The cell aggregates were
allowed to settle by gravity, and the dispase solution was gently aspirated. The aggregates were washed
three more times in DMEM/F12 before being resuspended in 12 ml of SF-EB medium. The suspension
was gently pipetted up and down to mix and 2 ml of medium/cell suspension was transferred to each well
of a 6 well ultra-low attachment plate (Costar 3471). A portion of 1 ml of SF-EB medium was then added
to each well to bring the total volume per well to 3 ml. Some SF-EBs were fed with growth factors or
chemical inhibitors (See section 2.4). The SF-EBs were cultured in suspension with 2/3 medium
exchanges on day 1 and day 3. SF-EBs were collected for analysis 2 and 5 days after being placed in
suspension.
2.4 Treatments
Some SF-EB groups were treated with growth factors or small molecule inhibitors. Human bFGF
(Peprotech 100-18B) was aliquoted in Tris-HCl (1 M, pH 7.5) to a concentration of 100 mg/ml and then
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further diluted to 10 mg/ml in 1% BSA. SF-EBs were treated with 10 ng/ml bFGF. The GSK3β inhibitor 6Bromoindirirubin-3’ oxide (BIO) (Sigma Aldrich B1686) was obtained from Sigma Aldrich and aliquoted in
DMSO to a stock concentration of 500 μM. SF-EBs were treated with BIO at a concentration between
100-1000 nM. Working solutions were stored at -20° C.
2.5 Microscopy
SF-EBs were examined daily under an inverted microscope and brightfield microscopy images
were taken on day 2-5 of the experiments using an Olympus IX71 inverted microscope and Slidebook
software. SF-EB diameters were determined using the Slidebook Imaging Analysis software.
2.6 Cell Counting
On days 2 and 5 of the experiment, SF-EBs were transferred to 15 ml tubes, rinsed with PBS,
and incubated in prewarmed Accutase (Stem cell Technologies 7920) for 5 min at 37° C. The suspension
was then pipetted up and down several times with a P1000 micropipette tip to produce a single cell
suspension. A portion of 3 ml of SF-EB medium were added to the single cell suspension to dilute the
accutase, and the tubes were centrifuged. The accutase was aspirated and the cells were resuspended
6

in SF-EB medium to an estimated density of 10 cells/ml. 20 μl of cell suspension was mixed with 20 μl of
trypan blue dye. 10 μl of solution was transferred to a hemacytometer (Hausser Scientific 3120), and the
4 corners were counted. Cells per milliter were calculated with the following equation:

2.7 Quantitative Real Time PCR (qRT-PCR)
RNA was extracted from SF-EBs using a RNeasy minikit from Qiagen (74134). RNA
concentration was determined using a Biotek Synergy Mx spectraphotometer with a Gen 5 Take 3
module. Ratios of absorbance at 260 and 280 nm were measured to determine the purity of the RNA.
Reverse transcription (RT) was carried out using Applied Biosystems High Capacity cDNA reverse
transcription kit (4368814) using the manufacturer’s protocol. qRT-PCR was carried out using the Power
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SYBR Green PCR Master Mix (Applied Biosystems 4368708). All components were kept on ice when not
in use. The reactions were carried out on an Eppendorf realplex4. Fold change calculations were
performed using the ΔΔCt method. The housekeeping gene was Beta actin. Undifferentiated H9 hESCs
were used as controls. See Appendix for detailed protocols. Primers used for qRT-PCR are listed in
Table 2.2.
Table 2.2 Primers for qRT-PCR.

2.8 Immunostaining
EBs were fixed in 4% paraformaldehyde (Sigma Aldrich P6148) for 20 min. Then they were
incubated at room temperature in a 7.5% Sucrose (Fluka 84097) solution in PBS for 3 h. Next, the EBs
were incubated with a 15 % sucrose solution in PBS overnight at 4º C. The EB/Sucrose solution was
transferred to a 15X15X5 mm vinyl freezing medium mold (Tissue Tek). The sucrose solution was
carefully aspirated, and enough freezing medium was added to fill the mold. The molds were frozen at 20 ºC and then either stored at –80ºC or used immediately for cryosectioning. 8 μm sections were
generated using the Triangle Biomedical Systems Minotome Plus. The sections were transferred to polyL-lysine coated slides (Electron Microscopy Sciences #63410) and stored at -80ºC until ready for use.
Slides were blocked in 1% BSA in PBST for 30 min. Antibodies were diluted in 1% BSA in PBST. The
following primary antibodies and dilutions were used: mouse monoclonal anti-E-cadherin 1:200 (Abcam
1416), rabbit monoclonal anti-β-catenin (dilution ration: 1:100) (Abcam 32572), rabbit polyclonal antiCollagen IV (dilution ratio: 1:100) (Abcam 6586). Samples were incubated with primary antibody at room
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temperature for 1 h.

The following secondary antibodies were used: Dylight 488 conjugated goat anti-

mouse IgG (dilution ratio:1:200) (Thermo Scientific 35503), TRITC-conjugated Affinipure Donkey Antirabbit IgG (dilution ratio:1:200) (Jackson Immuno Research 711-025-152). Samples were incubated with
secondary antibody for 1 h in the dark. Samples were counterstained with DAPI (Invitrogen) for 1 min in
the dark. See Appendix for detailed protocols.
2.9 Western Blot
SF-EBs were transferred to eppendorf tubes and rinsed with PBS. Samples were frozen at -80°C
until ready for lysing. Samples were lysed in RIPA lysis buffer.

The samples were denatured in loading

buffer at 95°C for 10 min. The proteins were resolved by 10% SDS-PAGE. The molecular weight
markers used were Pageruler Plus Prestained Protein Ladder (Thermo Scientific 26619). Wet transfer
was done using a nitrocellulose membrane (BIO-RAD 1101093).
The membrane was blocked using 5% milk in PBST for 1 h at 25°C. The primary antibody was
diluted in a blocking buffer. Samples were incubated overnight at 4°C. The membrane was washed 3x
times with PBST. The membrane was then incubated with HRP-conjugated secondary antibody in PBST
at room temperature under constant agitation for 1 h.

The samples were developed using the

SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific 34077).

Images were taken

using the BIO Rad Universal Hood II.
Anti-Beta Catenin Rabbit monoclonal antibody (Abcam ab32572) was used at 1:5000 dilution.
Beta actin HRP-conjugated antibody (Sigma Aldrich A3854) was used as a loading control.

Goat

polyclonal anti rabbit conjugated to HRP (Rockland 611-1302) was used as a secondary antibody. See
Appendix for detailed protocols.
2.10 Statisical Analysis
Single factor Analysis of Variance was performed with Tukey-Kramer Post-Hoc Analysis.

In

some cases, two tailed student’s t-tests were performed to obtain p values. Statistical significance was set
to p<0.05.
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Chapter 3 - Results
3.2 EB formation in a mTeSR1 compatible serum-free medium
First, we investigated the effect of EB medium composition on the efficiency of EB formation. H9
hESCs were grown on Matrigel coated plates and maintained in mTeSR1. When the cultures reached
approximately 70% confluency, they were incubated with 0.5 mg/ml dispase to dislodge them from the
plate, and the largely intact colonies were rinsed, resuspended and transferred to ultra low attachment
dishes. EBs would form within 24-48 h.
The efficiency of EB formation depended on the composition of the EB medium that the putative
EBs were fed. When EBs were formed in a medium containing knockout serum replacement (KOSR)
(Table 3.1), a proprietary serum replacement commonly used in the maintenance of feeder dependent
hPSCs, a large amount of cell debris and cell death was observed (Fig. 3.1) . We hypothesized that the
low efficiency of EB formation observed in a KOSR containing medium was due to medium incompatibility
and that EB formation from mTeSR1 adapted hPSCs could be improved if the EB medium was more
similar to mTeSR1 in its composition. To validate this hypothesis, we developed an EB formation medium
(Table 3.2) based on the published formulation of mTeSR1. This EB medium is serum-free and contains
all of the components of mTeSR1 except for the pluripotency factors (i.e. bFGF, TGFβ1, LiCl, GABA and
pipecolic acid). For clarity, this mTeSR1 based medium will hereafter be referred to as “serum-free EB
(SF-EB) medium” and EBs cultured in this medium will be referred to as SF-EBs.

Table 3.1 EB medium containing Knockout Serum Replacement

Component

1x concentration

Vendor

Catalog Number

DMEM/F-12 w/ L-glutamine

78%

Hyclone

SH30261.01

Knockout serum replacement

20%

10828-028

β-mercaptoethanol

0.1 mM

Invitrogen
EMD
Millipore

Non-Essential Amino Acids

1%

Hyclone

SH30238.01
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ES-007-E

Table 3.2 SF-EB medium
Component

1x concentration

Vendor

Catalog Number

DMEM/F12 w/ L-glutamine

79.3%

Hyclone

SH30261.01

BSA

12.96 mg/ml

Sigma Aldrich

A9418

Insulin

20 μg/ml

Gibco

41400-05

Transferrin

10 μg/ml

Gibco

41400-05

Glutamax

1%

Gibco

35050-061

β-mercaptoethanol

0.1 mM

EMD Millipore

ES-007-E

Non-Essential Amino Acids

1%

Hyclone

SH30238.01

Trace Elements B

0.20%

Cellgro

99-175-C1

Trace Elements C

0.10%

Cellgro

99-176-C1

Chemically Defined Lipids

0.00195 ml/ml

Gibco

11905-031

Na-Selenite

0.0306 μg/ml

Sigma Aldrich

S5261

Reduced Glutathione

1.96 μg/ml

Sigma Aldrich

G4251

Ascorbic Acid

45 μg/ml

Sigma Aldrich

A4544

Thiamine HCl

8.16 μg/ml

Sigma Aldrich

T1270

Sodium bicarbonate

0.544 mg/ml

Sigma Aldrich

S7277

NaCl

1.89 mg/ml

Acros

327300010

Figure 3.1. Micrographic images of EBs derived from H9 hESCs two days after formation. (A)
EBs in KOSR containing medium. (B) EBs in mTeSR1 compatible SF-EB medium.
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Unlike EBs formed in KOSR containing medium, SF-EBs formed in SF-EB medium appeared
healthy, and far less cell debris was observed during initial EB formation, suggesting a higher cell survival
rate (Fig 3.1B). The SF-EB medium was used for all subsequent experiments.
3.3 Without growth factor supplementation, SF-EBs tend to degrade in extended culture
Even though SF-EBs formed readily in SF-EB medium, they tended to degrade after a few days
in suspension culture. SF-EBs generated from both H9 hESCs and IMR90 hiPSCs, which had had been
largely round and symmetrical two days after SF-EB formation, began losing their characteristic round
shape starting on days 3-4 (Figure 3.2 B-C), and we observed increased amounts of cell debris in the
wells. By day 5 of suspension culture, most of the SF-EBs that had been fed the basal SF-EB medium
(hereafter called “control SF-EBs”) had become irregularly shaped or were falling apart.
3.4 Treatment with bFGF or small molecule inhibitors of GSK3β promotes improved SF-EB
morphology and growth.
It has been previously reported that treating EBs derived from mTeSR1 adapted cultures with
bFGF improves EB survival in suspension culture

72

. In order to investigate the effects of bFGF and

GSK3β inhibition on the development of SF-EBs, SF-EBs were generated in SF-EB medium (control),
SF-EB medium supplemented with 10 ng/ml bFGF or SF-EB medium supplemented with 300 nM of the
GSK3β inhibitor BIO. The SF-EBs were cultured in suspension for 5 days with medium refreshment
every other day.
After two days in suspension, we observed no significant difference between any of the three
treatment groups in terms of mean SF-EB diameter, viable cells per well or morphology. However, as
shown in Fig. 3.2, Fig. 3.3 and Fig 3.4, the SF-EBs showed great sensitivity to growth factor stimulation
and BIO treatment at later time points. On day 5 of suspension culture, both the bFGF and BIO treated
SF-EBs had significantly larger average diameters and higher cell counts per well than untreated control
SF-EBs. Interestingly, even though the bFGF and BIO treated SF-EBs' did not differ significantly in terms
of mean SF-EB diameter (Fig 3.3), bFGF treated SF-EBs did have a significantly higher viable cell count
per well than BIO treated SF-EBs, suggesting that cell density and proliferation rates were higher in bFGF
treated SF-EBs than BIO treated SF-EBs.
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Figure 3.2. Morphologies of hPSC-derived SF-EBs cultured under different conditions at different time
points. (A-D) H9 derived EBs cultured in SF-EB medium. (E-H) IMR90 hiPSC derived EBs cultured in SFEB medium. (I-L) H9 derived EBs cultured in SF-EB supplemented with GSK3β inhibitor BIO (300 nM)
(M-P) ) H9 derived EBs cultured in SF-EB supplemented with 10 ng/ml bFGF.

Treatment with either bFGF or BIO resulted in a more spherical morphology in SF-EBs compared
to untreated controls, though the morphologies of BIO treated SF-EBs were slightly more heterogeneous
than the bFGF treated SF-EBs. And BIO treatment, despite promoting cell proliferation overall, did not
prevent the accumulation of some cell debris in some experiments, an effect not observed in bFGF
treated SF-EBs.
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The effect of BIO was also strongly dose dependent. While treatment with 300 nM BIO was
sufficient to maintain SF-EB morphology and growth as compared to controls, increasing the
concentration of BIO to 500 nM resulted in widespread SF-EB agglomeration (Fig. 3.5).

This

agglomeration produced very large cellular aggregates. Such large agglomerations of SF-EBs would
likely limit oxygen and nutrient transport into the interior of the aggregates. Thus 300 nM BIO was used
for most experiments. Interestingly, the concentration of BIO used in our experiments (300 nM) was
considerably lower than the concentrations other groups have reported as being necessary for the
activation of canonical Wnt signaling in hPSCs in monolayer culture

41, 106
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Figure 3.3. Mean SF-EB diameter 2 and 5 days after EB formation (n=8). EBs were generated from
mTeSR1 adapted cultures and grown in suspension for 5 days. Some SF-EBs were treated with BIO
(300 nM) or bFGF (10 ng/ml). SF-EB diameters were determined via brightfield images analyzed with
Slidebook software. Average values are calculated from measurements of 20 randomly chosen SF-EBs
from each treatment group. * p<0.05 compared to control SF-EBs on day 5.
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Figure 3.4. Proliferation of cells in EBs performed 2 and 5 days after formation. Control EBs were grown
in suspension in SF-EB medium. BIO and bFGF EBs were grown in suspension in SF-EB medium plus
300 nM BIO or 10 ng/ml bFGF respectively. The data represents the average of three independent
experiments (n=3). Error bars represent standard deviation. * indicates p<0.05 by single factor ANOVA.

Figure 3.5. Agglomeration of SF-EBs at day 5 post EB formation in the presence of 500 nM BIO. Scale
bar = 100 μm.
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3.5 Cell-cell signaling within SF-EBs cultured under different conditions
We next hypothesized that the observed differences in SF-EB development as the result of
different bFGF or BIO treatment are correlated with differential expression of proteins associated with cell
adhesion. In order to test this hypothesis, we evaluated E-cadherin and β-catenin expression in SF-EBs
using immunostaining, qRT-PCR and western blot.
On day 2 or day 5 after SF-EB formation, SF-EBs were cut into 8 μm-thick sections using a
cryotome, placed on poly-L-lysine coated slides and subjected to immunofluorescence staining.

As

shown in Fig 3.6A(a-f), on day 2, E-cadherin and β-catenin were expressed throughout the SF-EBs
regardless of treatment, and the findings were confirmed for E-cadherin by qRT-PCR (Fig3.6C). These
results indicate that bFGF or BIO treatment of the SF-EBs had no apparent effect on the patterns of cellcell signaling at day 2 and that cell-cell signaling within day 2 SF-EBs from all three treatment groups is
dominated by E-cadherin, much as in undifferentiated hPSCs. The colocalization of β-catenin with Ecadherin may indicate that β-catenin is participating primarily in cell-cell signaling rather than canonical
Wnt signaling at this time point.

These patterns of cell-cell signaling coincide with the similar

morphologies observed in SF-EBs in all treatment groups at day 2.
However, differences in cell-cell signaling between the different treatment groups had become
apparent by day 5 post SF-EB formation. E-cadherin expression remained high in day 5 control SF-EBs
(Fig. 3.6A(g)). On the other hand, SF-EBs that had been treated with either 10 ng/ml bFGF or 300 nM
BIO showed evidence of decreased E-cadherin expression at the protein level (Fig. 3.6A(h-i)). In day 5
bFGF or BIO treated SF-EBs, E-cadherin tended to be localized to the outside of the EBs.

Some BIO

treated SF-EBs showed reduced E-cadherin expression, but with random localization (Fig3.6B). On day
5, there was no indication that control SF-EBs were down regulating E-cadherin. The differences in Ecadherin expression on day 5 between the different treatment groups was confirmed by qRT-PCR (Fig
3.6D). Strangely the E-cadherin mRNA expression in control SF-EBs was very high even compared to
undifferentiated H9s, which themselves express high levels of E-cadherin
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116

.

In control SF-EBs, β-catenin expression remained high on day 5, appearing to colocalize with Ecadherin. Some BIO treated samples showed β-catenin expression throughout the interior of the SF-EB,
indicating the presence of β-catenin in the cytoplasm and perhaps the nucleus (Fig 3.6A(h) and
Fig3.6B). The bFGF SF-EBs, on the other hand, show an overall reduction in β-catenin expression in the
areas of the SF-EB where E-cadherin expression is also reduced. Western blot analysis of whole cell
lysates from day 5 SF-EBs indicates that β-catenin levels are reduced in bFGF treated SF-EBs compared
to controls and BIO treated SF-EBs (Fig 3.7).
Reduced E-cadherin is associated with epithelial to mesenchymal transitions (EMTs) and hPSC
differentiation more generally

114

. E-cadherin down regulation as a result of EMT is often accompanied by

up regulation of other cell adhesion molecules such as N-cadherin and NCAM1. qRT-PCR shows that Ncadherin and NCAM1 are up regulated in BIO and bFGF treated SF-EBs compared to control SF-EBs
after 5 days in suspension (Fig3.6D).
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Figure 3.6. Cell-cell adhesion in SF-EBs. (A) Representative immunostaining results for β-catenin and Ecadherin expression in day 2 (a-f) and day 5 (g-l) SF-EBs cultured in SF-EB medium (Control), SF-EB
medium with 300 nM BIO or SF-EB medium with 10 ng/ml bFGF. Cells were counter-stained with DAPI.
Scale bar = 100 μm. (B) β-catenin and E-cadherin localization in some 300 nM BIO treated SF-EBs on
day 5. (C) qRT-PCR results for E-cadherin expression in day 2 EBs. (n=1). (D) qRT-PCR results for cell
adhesion molecules in differentiating day 5 SF-EBs (n=3). * indicates p<0.05 and ** indicates p<0.01 by
single factor Anova. Fold changes were calculated relative to undifferentiated H9s. β-actin was used as
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a housekeeping gene. p value in N-cadherin results calculated by two tailed student’s t-test. Error bars
represent standard deviation.

Figure 3.7. Western blot results for β-catenin expression in day 5 SF-EBs cultured in SF-EB medium
(Control), SF-EB medium with 300 nM BIO or SF-EB medium with 10 ng/ml bFGF. β-actin was used as a
loading control. (n=1).

Since transcription factors from the Snail and Twist family are known to inhibit the mRNA
expression of E-cadherin, we hypothesized that bFGF and BIO treated SF-EBs would have increased
mRNA expression of Snail, Slug and Twist1compared to control SF-EBs.

However qRT-PCR analysis

of Snail Slug and Twist1 expression in day 5 SF-EBs did not reveal a statistically significant difference
between treatment groups as determined by a two-tailed student’s t-test or single factor Anova (Fig3.8).
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Figure 3.8. qRT-PCR analysis of Snail (n=2), Slug and Twist1 (n=3) in SF-EBs at day 5. Fold changes
are determined relative to day 5 control SF-EBs. Error bars indicate standard deviation. p values are
determined by two tailed student’s t-test compared to Day 5 control SF-EBs.

3.5 Germ Layer Marker Expression in SF-EBs
One of the key developmental events commonly observed in EBs is the gradual reduction of
pluripotency marker expression and differentiation into cells from the three germ layers. We evaluated
pluripotency and germ layer expression in day 2 and day 5 SF-EBs fed SF-EB medium alone (control), or
SF-EB medium supplemented with either 300 nM BIO or 10 ng/ml bFGF.
As shown in Figs. 3.13A-B, mRNA expression of the pluripotency markers Oct4 and Nanog
decreased considerably in all groups over the course of five days in suspension (Fig3.9A-B). Germ layer
marker expression on the other hand was highly variable in all three treatment groups.

Consequently

there were no statistically significant differences among any of the treatment groups in terms of Brachyury
(Fig3.9C), NeuroD1 (Fig3.9D) or Sox17 (Fig3.9E) expression. Overall differentiation was biased in favor
of ectoderm. BIO treatment especially appeared to encourage ectoderm differentiation. Interestingly,
three germ layer differentiation is somewhat attenuated by bFGF, although the morphology and SF-EB
survival rate is improved by its inclusion in the EB culture medium.

31

Figure 3.9. qRT-PCR analysis of pluripotency and germ layer markers in differentiating SF-EBs at two
time points, day 2 and day 5. Control SF-EBs were grown in suspension in SF-EB medium. BIO and
bFGF SF-EBs were grown in suspension in SF-EB medium plus 300 nM BIO or 10 ng/ml bFGF
respectively. (A.) Oct 4. (B.) Nanog. (C.) Brachyruy (D.) Neurod1 (E.) Sox 17. Fold changes are
determined relative to undifferentiated H9s. β-actin was used as a housekeeping gene. p value was
determined by two tailed student’s t-test. Error bars indicate standard deviation.
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Chapter 4 – Discussion and Future Directions
In this study, we developed a serum free medium for the generation and culture of EBs from
mTeSR1 adapted hPSCs and to facilitate the study of signaling pathways that are important for EB
growth, cell-cell signaling and differentiation.

We found that EBs form readily when cultured in

suspension in mTeSR1 compatible SF-EB media, and these SF-EBs maintain their characteristically
round morphology for the first 48 hours of suspension culture. However, at later time points SF-EBs
begin to degrade, exhibiting defects in morphology and persistently high E-cadherin expression even as
pluripotency markers like Oct 4 and Nanog are down regulated.
Supplementing the SF-EB medium with bFGF rescues the morphology of the SF-EBs, and this is
in agreement with results obtained by other groups working with mTeSR1 adapted hPSCs.

This

sensitivity to growth factor withdrawal in EB culture distinguishes mTeSR1 adapted hPSCs from feeder
dependent hPSCs, which are routinely grown in suspension in serum free medium without growth factor
supplementation

68, 116

. It may be important to consider this sensitivity to growth factor withdrawal when

developing EB differentiation protocols for mTeSR1 adapted hPSCs.
In addition to bFGF, we found that modulating the activity of a single kinase, GSK3β, also
supports the improved growth, proliferation and morphology of SF-EBs. This suggests a role for GSK3β
in the early differentiation events of hPSCs and demonstrates the utility of small molecule inhibitors in
dissecting the mechanisms affecting hPSC differentiation and development in vitro.
GSK3β participates in numerous signaling pathways and interacts with many substrates that are
important for cell proliferation, survival and differentiation.

In future studies, it will be important to

investigate the signaling pathways that are affected by GSK3β inhibition in SF-EBs. One likely candidate
for investigation is the canonical Wnt pathway. GSK3β inhibitors are often used as activators of canonical
Wnt signaling. The timing of the control SF-EBs’ degradation in our experiments coincides with the onset
of canonical Wnt signaling reported for differentiating mEBs

136

. The observed defects in E-cadherin

regulation and SF-EB growth during the 5 day experiment is reminiscent of β-catenin null mEBs
generated by Lyashenko et al.
SF-EBs were equivocal.

113

. However our immunostaining results for β-catenin expression in day 5

In future studies, it will be important to target β-catenin more selectively.
33

Western blots of cytoplasmic and nuclear fractions at multiple time points can determine localization of βcatenin, and luciferase reporter assays can allow for the measurement of β-catenin/TCF complex
transcriptional activity

105

.

It is quite possible that other signaling pathways besides the canonical Wnt pathway are activated
in BIO treated SF-EBs. GSK3β inhibitors like BIO act on all of the GSK3β present within the cell

137

.

They are highly selective for the protein but cannot distinguish between separate pools of GSK3β. This
can be problematic since GSK3β is often regulated by intracellular localization and the formation of
complexes with other proteins

85

.

These separate pools of GSK3β act on different substrates and

participate in different pathways. For example, less than 10% of the GSK3β in a cell is involved in
canonical Wnt signaling

137

.

Thus GSK3β inhibition and canonical Wnt signaling are not necessarily

synonymous.
Also it is likely that GSK3β was only partially inhibited in the BIO treated SF-EBs as shown in this
study, as the concentration of BIO (300 nM) that we used was fairly low compared to the concentrations
104, 110

.

used by other researchers to activate canonical Wnt signaling in monolayer cultures (1-5 μM)

This is notable because other groups have reported that different amounts of GSK3β inhibition in
undifferentiated hPSCs exhibit threshold effects, with low concentrations of BIO stabilizing c-myc and
high concentrations activating canonical Wnt signaling

106

. In our study, a low concentration of BIO was

necessary as higher concentrations led to SF-EB agglomeration. In the future, it may be possible to
prevent SF-EB agglomeration by culturing the SF-EBs in an orbital shaker or stirred tank bioreactor. This
would allow for the use of higher concentrations of GSK3β inhibitors.
It is possible that maintenance of SF- EB morphology only requires the inactivation of a particular
pool of GSK3β.

Western blots of cytoplasmic and nuclear fractions of SF-EBs can determine the

localization of GSK3β as well as its phosphorylation status.
associated with cell apoptosis and cell cycle arrest

High GSK3β activity in the nucleus is

98

. Potential GSK3β targets that could affect the

survival and cell cycle progression of cells within SF-EBs include c-myc, cyclinD1, p53 and p27

98

. Also

in future experiments, flow cytometric analysis and BrdU incorporation assays may be used to assess cell
cycle progression and proliferation within SF-EBs.
34

The effects of GSK3β inhibition on E-cadherin expression suggests that GSK3β inactivation may
promote EMTs in SF-EBs. It is not clear whether GSK3β inhibition initiates EMT like events or if GSK3β
inhibition permits the survivaland proliferation of cells already undergoing EMT. Our qRT-PCR analysis of
the EMT promoting transcription factors Snail, Slug and Twist1 revealed no significant difference between
SF-EBs with and without bFGF or BIO treatment. However GSK3β is known to affect the stability of
these proteins. Thus western blots may reveal differences in expression between different treatment
groups not evident at the level of transcription.
The ability of small molecule inhibitors of GSK3β to support SF-EB survival may prove useful for
the development of EB-based hPSC differentiation protocols for the generation of GMP grade somatic
cells for applications in regenerative medicine. GSK3β inhibition has been used in concert with other
small molecule inhibitors and growth factors to generate definitive endoderm, mesoderm, as well as
neural progenitors, neural stem cells and neural crest stem cells

106, 112, 138-140

. Reducing the need for

growth factor stimulation has the potential to greatly reduce the cost associated with pluripotent stem cell
research. Also selective small molecule inhibitors allow researchers to target specific proteins, and this
could deepen our understanding of the signaling pathways controlling early embryological development.
The SF-EB medium may be especially useful in generation of neural progenitors or neural crest
cells with small molecules, as the early neural marker NeuroD1 was highly up regulated in of BIO treated
SF-EBs (Fig. 3.12E). Adopting differentiation protocols that replace growth factors with small molecules
promises to reduce costs and allow for the production of matured cell types in more defined conditions

139

.

Of course, patterns of three germ layer expression on day 5 were highly variable in all groups, but
regardless of treatment, differentiation at 5 days post SF-EB formation was strongly biased towards
ectoderm. This result is in agreement with Bock et al

141

. In future studies it will be important to examine

SF-EB derived cells at later time points to confirm that early differentiation marker expression accurately
reflects the ultimate fate decisions of those cells and to characterize these cells’ ability to give rise to
terminally differentiated cell types.
It is possible that the weak mesendodermal marker expression we observed in all three treatment
groups could be due in part to the composition of the SF-EB medium. mTeSR1 has a very high insulin
35

concentration-- approximately 20 μg/mL-- and since the SF-EB medium is modeled on mTeSR1, it has a
similarly high insulin concentration. Freund et al. have reported that insulin treatment in hESCs prevents
mesendoderm differentiation and favors neuroectodermal differentiation

142

. However another group

argues that insulin does not prevent all mesendoderm differentiation, but it does attenuate differentiation
into cardiac mesoderm

143

.

It might be advantageous in future experiments to find ways of reducing the

insulin concentration in the SF-EB medium without compromising the SF-EB medium’s compatibility with
mTeSR1, especially if the goal is to direct hPSC differentiation into mesendodermal lineages.
In conclusion, we demonstrate that chemical inhibition of GSK3β is sufficient to support the
growth of EBs derived from mTeSR1 adapted hPSCs. The use of small molecules to direct hPSC
differenitation may help facilitate the development of defined culture conditions, which is necessary step
in the transition of hPSCs from bench to clinic.

36

References

1.

Thomson, J.A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282,
1145-1147 (1998).

2.

Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A. & Bongso, A. Embryonic stem cell lines
from human blastocysts: somatic differentiation in vitro. Nat. Biotechnol. 18, 399-404 (2000).

3.

Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131, 861-872 (2007).

4.

Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318,
1917-1920 (2007).

5.

Carey, B.W. et al. Reprogramming of murine and human somatic cells using a single polycistronic
vector. Proc Natl Acad Sci U S A 106, 157-162 (2009).

6.

Zhou, W. & Freed, C.R. Adenoviral gene delivery can reprogram human fibroblasts to induced
pluripotent stem cells. Stem Cells 27, 2667-2674 (2009).

7.

Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences.
Science 324, 797-801 (2009).

8.

Woltjen, K. et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.
Nature 458, 766-770 (2009).

9.

Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of
human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630 (2010).

10.

Izpisua Belmonte, J.C., Ellis, J., Hochedlinger, K. & Yamanaka, S. Induced pluripotent stem cells
and reprogramming: seeing the science through the hype. Nat Rev Genet 10, 878-883 (2009).

11.

Boyd, A.S., Rodrigues, N.P., Lui, K.O., Fu, X. & Xu, Y. Concise review: Immune recognition of
induced pluripotent stem cells. Stem Cells 30, 797-803 (2012).

12.

Srivastava, A.S., Malhotra, R., Sharp, J. & Berggren, T. Potentials of ES Cell Therapy in
Neurodegenerative Diseases. Curr. Pharm. Design 14, 3873-3879 (2008).

13.

Lukovic, D., Manzano, V.M., Stojkovic, M., Bhattacharya, S.S. & Erceg, S. Concise Review:
Human Pluripotent Stem Cells in the Treatment of Spinal Cord Injury. Stem Cells 30, 1787-1792
(2012).

14.

Noguchi, H. Production of pancreatic beta-cells from stem cells. Current diabetes reviews 6, 184190 (2010).

15.

Ameen, C. et al. Human embryonic stem cells: Current technologies and emerging industrial
applications. Crit. Rev. Oncol./Hematol. 65, 54-80 (2008).

16.

Frantz, S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat. Biotechnol. 30, 12-13
(2012).

17.

Schwartz, S.D. et al. Embryonic stem cell trials for macular degeneration: a preliminary report.
Lancet 379, 713-720 (2012).

37

18.

Pouton, C.W. & Haynes, J.M. Pharmaceutical applications of embryonic stem cells. Adv. Drug
Deliv. Rev. 57, 1918-1934 (2005).

19.

Dvash, T. & Benvenisty, N. Human embryonic stem cells as a model for early human
development. Best Pract. Res. Clin. Obstet. Gynaecol. 18, 929-940 (2004).

20.

Briggs, J.A. et al. Integration-free induced pluripotent stem cells model genetic and neural
developmental features of down syndrome etiology. Stem Cells 31, 467-478 (2013).

21.

Yung, S.K. et al. Brief report: human pluripotent stem cell models of fanconi anemia deficiency
reveal an important role for fanconi anemia proteins in cellular reprogramming and survival of
hematopoietic progenitors. Stem Cells 31, 1022-1029 (2013).

22.

Park, I.H. et al. Disease-specific induced pluripotent stem cells. Cell 134, 877-886 (2008).

23.

Brennand, K.J. et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature
473, 221-225 (2011).

24.

Pera, M.F. & Trounson, A.O. Human embryonic stem cells: prospects for development.
Development 131, 5515-5525 (2004).

25.

Zhang, X. et al. Derivation of human embryonic stem cells from developing and arrested
embryos. Stem Cells 24, 2669-2676 (2006).

26.

Boyer, L.A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell
122, 947-956 (2005).

27.

Vallier, L., Alexander, M. & Pedersen, R.A. Activin/Nodal and FGF pathways cooperate to
maintain pluripotency of human embryonic stem cells. J. Cell Sci. 118, 4495-4509 (2005).

28.

Ludwig, T.E. et al. Derivation of human embryonic stem cells in defined conditions. Nat.
Biotechnol. 24, 185-187 (2006).

29.

Wang, L. et al. Self-renewal of human embryonic stem cells requires insuhn-like growth factor-1
receptor and ERBB2 receptor signaling. Blood 110, 4111-4119 (2007).

30.

Dalton, S. Signaling networks in human pluripotent stem cells. Curr Opin Cell Biol (2012).

31.

Tesar, P.J. et al. New cell lines from mouse epiblast share defining features with human
embryonic stem cells. Nature 448, 196-U110 (2007).

32.

Richards, M. et al. Comparative evaluation of various human feeders for prolonged
undifferentiated growth of human embryonic stem cells. Stem Cells 21, 546-556 (2003).

33.

Prowse, A.B.J., McQuade, L.R., Bryant, K.J., Marcal, H. & Gray, P.P. Identification of potential
pluripotency determinants for human embryonic stem cells following proteomic analysis of human
and mouse fibroblast conditioned media. J. Proteome Res. 6, 3796-3807 (2007).

34.

Greber, B., Lehrach, H. & Adjaye, J. Fibroblast growth factor 2 modulates transforming growth
factor beta signaling in mouse embryonic fibroblasts and human ESCs (hESCs) to support hESC
self-renewal. Stem Cells 25, 455-464 (2007).

35.

Xu, C.H. et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat.
Biotechnol. 19, 971-974 (2001).

38

36.

Kleinman, H.K. & Martin, G.R. Matrigel: Basement membrane matrix with biological activity.
Semin. Cancer Biol. 15, 378-386 (2005).

37.

Villa-Diaz, L.G., Ross, A.M., Lahann, J. & Krebsbach, P.H. Concise review: The evolution of
human pluripotent stem cell culture: from feeder cells to synthetic coatings. Stem Cells 31, 1-7
(2013).

38.

Martin, M.J., Muotri, A., Gage, F. & Varki, A. Human embryonic stem cells express an
immunogenic nonhuman sialic acid. Nat. Med. 11, 228-232 (2005).

39.

Ludwig, T.E. et al. Feeder-independent culture of human embryonic stem cells. Nat. Methods 3,
637-646 (2006).

40.

Xu, R.H. et al. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation
of human ES cells. Nat. Methods 2, 185-190 (2005).

41.

Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. & Brivanlou, A.H. Maintenance of pluripotency
in human and mouse embryonic stem cells through activation of Wnt signaling by a
pharmacological GSK-3-specific inhibitor. Nat. Med. 10, 55-63 (2004).

42.

Sperger, J.M. et al. Gene expression patterns in human embryonic stem cells and human
pluripotent germ cell tumors. Proc Natl Acad Sci U S A 100, 13350-13355 (2003).

43.

Braam, S.R. et al. Recombinant vitronectin is a functionally defined substrate that supports
human embryonic stem cell self-renewal via alpha V beta 5 integrin. Stem Cells 26, 2257-2265
(2008).
Villa-Diaz, L.G. et al. Synthetic polymer coatings for long-term growth of human embryonic stem
cells. Nat. Biotechnol. 28, 581-583 (2010).

44.
45.

Melkoumian, Z. et al. Synthetic peptide-acrylate surfaces for long-term self-renewal and
cardiomyocyte differentiation of human embryonic stem cells. Nat. Biotechnol. 28, 606-U695
(2010).

46.

Chen, G.K. et al. Chemically defined conditions for human iPSC derivation and culture. Nat.
Methods 8, 424-U476 (2011).

47.

Akopian, V. et al. Comparison of defined culture systems for feeder cell free propagation of
human embryonic stem cells. In Vitro Cell. Dev. Biol.-Anim. 46, 247-258 (2010).

48.

Yoon, T.M. et al. Human Embryonic Stem Cells (hESCs) Cultured Under Distinctive Feeder-Free
Culture Conditions Display Global Gene Expression Patterns Similar to hESCs from FeederDependent Culture Conditions. Stem Cell Rev. Rep. 6, 425-437 (2010).

49.

Hannoun, Z. et al. The comparison between conditioned media and serum-free media in human
embryonic stem cell culture and differentiation. Cell Reprogram 12, 133-140 (2010).

50.

Cao, J. et al. Fourier transform infrared microspectroscopy reveals unique phenotypes for human
embryonic and induced pluripotent stem cell lines and their progeny. J Biophotonics 25,
201200217 (2013).

51.

Tompkins, J.D. et al. Epigenetic stability, adaptability, and reversibility in human embryonic stem
cells. Proc. Natl. Acad. Sci. U. S. A. 109, 12544-12549 (2012).

52.

Blauwkamp, T.A., Nigam, S., Ardehali, R., Weissman, I.L. & Nusse, R. Endogenous Wnt
signalling in human embryonic stem cells generates an equilibrium of distinct lineage-specified
progenitors. Nat Commun 3 (2012).
39

53.

Ojala, M. et al. Culture Conditions Affect Cardiac Differentiation Potential of Human Pluripotent
Stem Cells. PLoS One 7 (2012).

54.

Sharon, N., Mor, I., Golan-lev, T., Fainsod, A. & Benvenisty, N. Molecular and Functional
Characterizations of Gastrula Organizer Cells Derived from Human Embryonic Stem Cells. Stem
Cells 29, 600-608 (2011).

55.

Fuchs, C. et al. Self-Organization Phenomena in Embryonic Stem Cell-Derived Embryoid Bodies:
Axis Formation and Breaking of Symmetry during Cardiomyogenesis. Cells Tissues Organs 195,
377-391 (2012).

56.

Ungrin, M.D., Joshi, C., Nica, A., Bauwens, C. & Zandstra, P.W. Reproducible, Ultra HighThroughput Formation of Multicellular Organization from Single Cell Suspension-Derived Human
Embryonic Stem Cell Aggregates. PLoS One 3 (2008).

57.

Maurer, J. et al. Contrasting Expression of Keratins in Mouse and Human Embryonic Stem Cells.
PLoS One 3 (2008).

58.

Li, X.F. et al. Fibroblast growth factor signaling and basement membrane assembly are
connected during epithelial morphogenesis of the embryoid body. J. Cell Biol. 153, 811-822
(2001).

59.

Sachlos, E. & Auguste, D.T. Embryoid body morphology influences diffusive transport of inductive
biochemicals: A strategy for stem cell differentiation. Biomaterials 29, 4471-4480 (2008).

60.

Bratt-Leal, A.M., Carpenedo, R.L. & McDevitt, T.C. Engineering the Embryoid Body
Microenvironment to Direct Embryonic Stem Cell Differentiation. Biotechnol. Prog. 25, 43-51
(2009).

61.

Van Winkle, A.P., Gates, I.D. & Kallos, M.S. Mass Transfer Limitations in Embryoid Bodies during
Human Embryonic Stem Cell Differentiation. Cells Tissues Organs 196, 34-47 (2012).

62.

Schulz, T.C. et al. A Scalable System for Production of Functional Pancreatic Progenitors from
Human Embryonic Stem Cells. PLoS One 7 (2012).

63.

Carpenedo, R.L. et al. Homogeneous and organized differentiation within embryoid bodies
induced by microsphere-mediated delivery of small molecules. Biomaterials 30, 2507-2515
(2009).

64.

Ng, E.S., Davis, R.P., Azzola, L., Stanley, E.G. & Elefanty, A.G. Forced aggregation of defined
numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible
hematopoietic differentiation. Blood 106, 1601-1603 (2005).

65.

Chadwick, K. et al. Cytokines and BMP-4 promote hematopoietic differentiation of human
embryonic stem cells. Blood 102, 906-915 (2003).

66.

Kehat, I. et al. Human embryonic stem cells can differentiate into myocytes with structural and
functional properties of cardiomyocytes. J. Clin. Invest. 108, 407-414 (2001).

67.

Khoo, M.L.M. et al. Growth and differentiation of embryoid bodies derived from human embryonic
stem cells: Effect of glucose and basic fibroblast growth factor. Biol. Reprod. 73, 1147-1156
(2005).

68.

Itskovitz-Eldor, J. et al. Differentiation of human embryonic stem cells into embryoid bodies
comprising the three embryonic germ layers. Mol. Med. 6, 88-95 (2000).
40

69.

Mummery, C.L. et al. Differentiation of human embryonic stem cells and induced pluripotent stem
cells to cardiomyocytes: a methods overview. Circ Res 111, 344-358 (2012).

70.

Antonchuk, J., et al. 7th annual meeting of the International Society for Stem Cell Research;
(2009).

71.

Antonchuk, J. in Methods in molecular biology (Clifton, N.J.), Vol. 946 523-533 (2013).

72.

Shevde, N.K. & Mael, A.A. in Methods in molecular biology (Clifton, N.J.), Vol. 946 535-546
(2012).

73.

Dailey, L., Ambrosetti, D., Mansukhani, A. & Basilico, C. Mechanisms underlying differential
responses to FGF signaling. Cytokine Growth Factor Rev. 16, 233-247 (2005).

74.

Wang, X.F., Lin, G., Martins-Taylor, K., Zeng, H. & Xu, R.H. Inhibition of Caspase-mediated
Anoikis Is Critical for Basic Fibroblast Growth Factor-sustained Culture of Human Pluripotent
Stem Cells. J. Biol. Chem. 284, 34054-34064 (2009).

75.

Zhang, S.C., Wernig, M., Duncan, I.D., Brustle, O. & Thomson, J.A. In vitro differentiation of
transplantable neural precursors from human embryonic stem cells. Nat. Biotechnol. 19, 11291133 (2001).

76.

Li, X.J. et al. Specification of motoneurons from human embryonic stem cells. Nat. Biotechnol. 23,
215-221 (2005).

77.

Itsykson, P. et al. Derivation of neural precursors from human embryonic stem cells in the
presence of noggin. Mol. Cell. Neurosci. 30, 24-36 (2005).

78.

Greber, B. et al. FGF signalling inhibits neural induction in human embryonic stem cells. Embo J.
30, 4874-4884 (2011).

79.

Yu, P.Z., Pan, G.J., Yu, J.Y. & Thomson, J.A. FGF2 Sustains NANOG and Switches the Outcome
of BMP4-Induced Human Embryonic Stem Cell Differentiation. Cell Stem Cell 8, 326-334 (2011).

80.

Israsena, N., Hu, M., Fu, W.M., Kan, L.X. & Kessler, J.A. The presence of FGF2 signaling
determines whether beta-catenin exerts effects on proliferation or neuronal differentiation of
neural stem cells. Dev. Biol. 268, 220-231 (2004).

81.

Ciruna, B. & Rossant, J. FGF signaling regulates mesoderm cell fate specification and
morphogenetic movement at the primitive streak. Dev. Cell 1, 37-49 (2001).

82.

Ding, V.M.Y. et al. FGF-2 Modulates Wnt Signaling in Undifferentiated hESC and iPS Cells
Through Activated PI3-K/GSK3 beta Signaling. J. Cell. Physiol. 225, 417-428 (2010).

83.

Hay, E.D. The mesenchymal cell, its role in the embryo, and the remarkable signaling
mechanisms that create it. Dev Dyn 233, 706-720 (2005).

84.

Moon, R.T., Bowerman, B., Boutros, M. & Perrimon, N. The promise and perils of Wnt signaling
through beta-catenin. Science 296, 1644-1646 (2002).

85.

Kaidanovich-Beilin, O. & Woodgett, J.R. GSK-3: Functional Insights from Cell Biology and Animal
Models. Frontiers in molecular neuroscience 4, 40 (2011).

86.

Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. beta-catenin is a target for the
ubiquitin-proteasome pathway. Embo J. 16, 3797-3804 (1997).
41

87.

Woodgett, J.R. MOLECULAR-CLONING AND EXPRESSION OF GLYCOGEN-SYNTHASE
KINASE-3 FACTOR-A. Embo J. 9, 2431-2438 (1990).

88.

Woodgett, J.R. REGULATION AND FUNCTIONS OF THE GLYCOGEN-SYNTHASE KINASE-3
SUBFAMILY. Semin. Cancer Biol. 5, 269-275 (1994).

89.

Cross, D.A.E., Alessi, D.R., Cohen, P., Andjelkovich, M. & Hemmings, B.A. INHIBITION OF
GLYCOGEN-SYNTHASE KINASE-3 BY INSULIN-MEDIATED BY PROTEIN-KINASE-B. Nature
378, 785-789 (1995).

90.

Sutherland, C., Leighton, I.A. & Cohen, P. INACTIVATION OF GLYCOGEN-SYNTHASE
KINASE-3-BETA BY PHOSPHORYLATION - NEW KINASE CONNECTIONS IN INSULIN AND
GROWTH-FACTOR SIGNALING. Biochem. J. 296, 15-19 (1993).

91.

Delcommenne, M. et al. Phosphoinositide-3-OH kinase-dependent regulation of glycogen
synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci.
U. S. A. 95, 11211-11216 (1998).

92.

Stambolic, V. & Woodgett, J.R. MITOGEN INACTIVATION OF GLYCOGEN-SYNTHASE
KINASE-3-BETA IN INTACT-CELLS VIA SERINE-9 PHOSPHORYLATION. Biochem. J. 303,
701-704 (1994).

93.

Fang, X.J. et al. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase
A. Proc. Natl. Acad. Sci. U. S. A. 97, 11960-11965 (2000).

94.

Saito, Y., Vandenheede, J.R. & Cohen, P. THE MECHANISM BY WHICH EPIDERMAL
GROWTH-FACTOR INHIBITS GLYCOGEN-SYNTHASE KINASE 3 IN A431 CELLS. Biochem. J.
303, 27-31 (1994).

95.

Ding, Q.Q. et al. Erk associates with and primes GSK-3 beta for its inactivation resulting in
upregulation of beta-catenin. Mol. Cell 19, 159-170 (2005).

96.

Thornton, T.M. et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3 beta
inactivation. Science 320, 667-670 (2008).

97.

Kim, L., Liu, J.C. & Kimmel, A.R. The novel tyrosine kinase ZAK1 activates GSK3 to direct cell
fate specification. Cell 99, 399-408 (1999).

98.

Sutherland, C. What Are the bona fide GSK3 Substrates? Int J Alzheimers Dis 505607, 18
(2011).

99.

Grimes, C.A. & Jope, R.S. The multifaceted roles of glycogen synthase kinase 3 beta in cellular
signaling. Prog. Neurobiol. 65, 391-426 (2001).

100.

Watcharasit, P. et al. Glycogen synthase kinase-3 beta (GSK3 beta) binds to and promotes the
actions of p53. J. Biol. Chem. 278, 48872-48879 (2003).

101.

Surjit, M. & Lal, S.K. Glycogen synthase kinase-3 phosphorylates and regulates the stability of
p27kip1 protein. Cell Cycle 6, 580-588 (2007).

102.

Forde, J.E. & Dale, T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life
Sci 64, 1930-1944 (2007).

103.

Zoumaro-Djayoon, A.D. et al. Investigating the role of FGF-2 in stem cell maintenance by global
phosphoproteomics profiling. Proteomics 11, 3962-3971 (2011).
42

104.

Singh, A.M., Bechard, M., Smith, K. & Dalton, S. Reconciling the different roles of Gsk3 beta in
"naive" and "primed" pluripotent stem cells. Cell Cycle 11, 2991-2996 (2012).

105.

Davidson, K.C. et al. Wnt/β-catenin signaling promotes differentiation, not self-renewal, of human
embryonic stem cells and is repressed by Oct4. Proc Natl Acad Sci U S A 109, 4485-4490
(2012).

106.

Singh, A.M. et al. Signaling Network Crosstalk in Human Pluripotent Cells: A Smad2/3-Regulated
Switch that Controls the Balance between Self-Renewal and Differentiation. Cell Stem Cell 10,
312-326 (2012).

107.

Jin, S., Yao, H.T., Krisanarungson, P., Haukas, A. & Ye, K.M. Porous Membrane Substrates Offer
Better Niches to Enhance the Wnt Signaling and Promote Human Embryonic Stem Cell Growth
and Differentiation. Tissue Eng. Part A 18, 1419-1430 (2012).

108.

Carpenter, M.K. et al. Properties of four human embryonic stem cell lines maintained in a feederfree culture system. Dev. Dyn. 229, 243-258 (2004).

109.

Ullmann, U. et al. GSK-3-specific inhibitor-supplemented hESC medium prevents the epithelialmesenchymal transition process and the up-regulation of matrix metalloproteinases in hESCs
cultured in feeder-free conditions. Mol. Hum. Reprod. 14, 169-179 (2008).

110.

Sumi, T., Tsuneyoshi, N., Nakatsuji, N. & Suemori, H. Defining early lineage specification of
human embryonic stem cells by the orchestrated balance of canonical Wnt/beta-catenin,
Activin/Nodal and BMP signaling. Development 135, 2969-2979 (2008).

111.

Arnold, S.J. et al. Brachyury is a target gene of the Wnt/beta-catenin signaling pathway. Mech.
Dev. 91, 249-258 (2000).

112.

Menendez, L., Yatskievych, T.A., Antin, P.B. & Dalton, S. Wnt signaling and a Smad pathway
blockade direct the differentiation of human pluripotent stem cells to multipotent neural crest cells.
Proc. Natl. Acad. Sci. U. S. A. 108, 19240-19245 (2011).

113.

Lyashenko, N. et al. Differential requirement for the dual functions of beta-catenin in embryonic
stem cell self-renewal and germ layer formation. Nat. Cell Biol. 13, 753-U365 (2011).

114.

Eastham, A.M. et al. Epithelial-mesenchymal transition events during human embryonic stem cell
differentiation. Cancer Res. 67, 11254-11262 (2007).

115.

Campbell, S., Swann, H.R., Seif, M.W., Kimber, S.J. & Aplin, J.D. CELL-ADHESION
MOLECULES ON THE OOCYTE AND PREIMPLANTATION HUMAN EMBRYO. Hum. Reprod.
10, 1571-1578 (1995).

116.

Dang, S.M., Gerecht-Nir, S., Chen, J., Itskovitz-Eldor, J. & Zandstra, P.W. Controlled, scalable
embryonic stem cell differentiation culture. Stem Cells 22, 275-282 (2004).

117.

Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem
cells. Nat. Biotechnol. 25, 681-686 (2007).

118.

Ohgushi, M. et al. Molecular Pathway and Cell State Responsible for Dissociation-Induced
Apoptosis in Human Pluripotent Stem Cells. Cell Stem Cell 7, 225-239 (2010).

119.

Hwang, Y.S. et al. Microwell-mediated control of embryoid body size regulates embryonic stem
cell fate via differential expression of WNT5a and WNT11. Proc Natl Acad Sci U S A 106, 1697816983 (2009).
43

120.

Cai, J.L. et al. Development of antibodies to human embryonic stem cell antigens. BMC Dev. Biol.
5, 7 (2005).

121.

Wheelock, M.J. & Johnson, K.R. Cadherins as modulators of cellular phenotype. Annu Rev Cell
Dev Biol 19, 207-235 (2003).

122.

McCrea, P.D., Gu, D. & Balda, M.S. Junctional music that the nucleus hears: cell-cell contact
signaling and the modulation of gene activity. Cold Spring Harb Perspect Biol 1 (2009).

123.

Heuberger, J. & Birchmeier, W. Interplay of Cadherin-Mediated Cell Adhesion and Canonical Wnt
Signaling. Cold Spring Harbor Perspect. Biol. 2 (2010).

124.

Lim, J. & Thiery, J.P. Epithelial-mesenchymal transitions: insights from development.
Development 139, 3471-3486 (2012).

125.

Spencer, H.L. et al. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal
antigen in mouse embryonic stem cells. Mol. Biol. Cell 18, 2838-2851 (2007).

126.

Nandadasa, S., Tao, Q., Menon, N.R., Heasman, J. & Wylie, C. N- and E-cadherins in Xenopus
are specifically required in the neural and non-neural ectoderm, respectively, for F-actin assembly
and morphogenetic movements. Development 136, 1327-1338 (2009).

127.

Elkabetz, Y. et al. Human ES cell-derived neural rosettes reveal a functionally distinct early neural
stem cell stage. Genes Dev. 22, 152-165 (2008).

128.

D'Amour, K.A. et al. Efficient differentiation of human embryonic stem cells to definitive
endoderm. Nat. Biotechnol. 23, 1534-1541 (2005).

129.

Pruszak, J., Sonntag, K.C., Aung, M.H., Sanchez-Pernaute, R. & Isacson, O. Markers and
methods for cell sorting of human embryonic stem cell-derived neural cell Populations. Stem
Cells 25, 2257-2268 (2007).

130.

Evseenko, D. et al. Mapping the first stages of mesoderm commitment during differentiation of
human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 107, 13742-13747 (2010).

131.

Zhou, B.H.P. et al. Dual regulation of Snail by GSK-3 beta-mediated phosphorylation in control of
epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931-+ (2004).

132.

Bachelder, R.E., Yoon, S.O., Franci, C., de Herreros, A.G. & Mercurio, A.M. Glycogen synthase
kinase-3 is an endogenous inhibitor of snail transcription: implications for the epithelialmesenchymal transition. J. Cell Biol. 168, 29-33 (2005).

133.

Lander, R. et al. Interactions between Twist and other core epithelial-mesenchymal transition
factors are controlled by GSK3-mediated phosphorylation. Nature communications 4, 1542
(2013).

134.

Katoh, M. Cross-talk of WNT and FGF signaling pathways at GSK3 beta to regulate beta-catenin
and SNAIL signaling cascades. Cancer Biol. Ther. 5, 1059-1064 (2006).

135.

Woods, N.B. et al. Brief Report: Efficient Generation of Hematopoietic Precursors and
Progenitors from Human Pluripotent Stem Cell Lines. Stem Cells 29, 1158-1164.

136.

ten Berge, D. et al. Wnt Signaling Mediates Self-Organization and Axis Formation in Embryoid
Bodies. Cell Stem Cell 3, 508-518 (2008).

44

137.

Voskas, D., Ling, L.S. & Woodgett, J.R. Does GSK-3 provide a shortcut for PI3K activation of Wnt
signalling? F1000 biology reports 2, 82 (2010).

138.

Bone, H.K., Nelson, A.S., Goldring, C.E., Tosh, D. & Welham, M.J. A novel chemically directed
route for the generation of definitive endoderm from human embryonic stem cells based on
inhibition of GSK-3. J. Cell Sci. 124, 1992-2000.

139.

Reinhardt, P. et al. Derivation and Expansion Using Only Small Molecules of Human Neural
Progenitors for Neurodegenerative Disease Modeling. PLoS One 8, e59252 (2013).

140.

Li, W. et al. Rapid induction and long-term self-renewal of primitive neural precursors from human
embryonic stem cells by small molecule inhibitors. Proc Natl Acad Sci U S A 108, 8299-8304
(2011).

141.

Bock, C. et al. Reference Maps of Human ES and iPS Cell Variation Enable High-Throughput
Characterization of Pluripotent Cell Lines. Cell 144, 439-452.

142.

Freund, C. et al. Insulin redirects differentiation from cardiogenic mesoderm and endoderm to
neuroectoderm in differentiating human embryonic stem cells. Stem Cells 26, 724-733 (2008).

143.

Lian, X.J., Zhang, J.H., Zhu, K.X., Kamp, T.J. & Palecek, S.P. Insulin Inhibits Cardiac Mesoderm,
Not Mesendoderm, Formation During Cardiac Differentiation of Human Pluripotent Stem Cells
and Modulation of Canonical Wnt Signaling Can Rescue This Inhibition. Stem Cells 31, 447-457
(2013).

45

Appendix
Preparation of mTeSR1 (Stem Cell Technologies 05850)
1. mTeSR1 basal medium is stored at 4 °C. The 5 x supplement is kept at -20 °C until use.
2. Thaw 100 ml bottle of 5 x supplement.
3. Aliquot 5 x supplement to 10 ml aliquots in 15 ml centrifuge tubes (Corning 430790).
4. Store aliquots at -20 °C.
5. To make 50 ml of mTeSR1:
a. 40 ml of mTeSR1 basal medium
b. 10 ml 5 x supplement
6. Mix well.
7. mTeSR1 can be stored at 4 °C for two weeks.
Aliquoting BD Matrigel (BD Biosciences 354230)
1. Matrigel is liquid at 4 °C, but it gels rapidly at room temperature. So aliquot Matrigel under
aseptic conditions and keep all reagents on ice.
2. Thaw Matrigel on ice at 4 °C.
3. In biological safety cabinet, make 10 and 30 μl aliquots of Matrigel in 1.5 ml eppendorf tubes
(VWR 20170-38).
4. Aliquots are stored at – 80 °C.
Coating tissue culture treated plates with BD Matrigel
1. Thaw aliquot of BD Matrigel at 4 °C.
2. Dilute Matrigel at 1:150 in DMEM/F-12 (Hyclone SH30261.01), e.g. 10 μl in 1.5 ml DMEM/F12
3.

Add Matrigel to plate:
a. 1 ml for 35 mm dish
b. 2.5 ml for 60 mm dish
c.

7.5 ml for 100 mm dish

4. Let stand in the hood for at least 1 hour before plating cells.
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Thawing hPSCs for culture in mTeSR1
1. Coat a 35 or 60 mm tissue culture treated plate (Corning 430165, 430166) with BD Matrigel
2. Prewarm 7 ml of mTeSR1 to dilute freezing medium plus enough mTeSr1 to resuspend and
culture the hPSCs (e.g. 2 ml for a 35 mm dish, 4 ml for 60 mm dish).
3. Retrieve cell aliquot from liquid nitrogen storage.
4. Place aliquot in 37 °C water bath, but be careful to not allow the cap to become submerged, as
this may lead to contamination.
5. Gently swirl the aliquot until only a small bit of ice remains.
6. Take the aliquot into a biological safety cabinet.
7. Transfer aliquot to a 15 ml centrifuge tube.
8. Add prewarm mTeSR1 to the tube dropwise to dilute the aliquot in 7 ml prewarmed mTeSR1.
9. Centrifuge the cell suspension for 5 minutes at 300 x g.
10. Apsirate the supernatant.
11. Resuspend cell pellet in the appropriate volume of mTeSR1 (2 or 4 ml usually).
12. Apsirate DMEM/F-12/Matrigel solution from the tissue culture treated plate.
13. Transfer the mTeSR1/cell suspension to the plate.
14. Label the plate with cell type, passage number, date and initials.
15. Gently shake the plate back and forth and side to side to evenly distribute the colonies on the
plate.
16. Place plate in 5 % CO2 incubator at 37 °C.
17. Change hPSC medium every day until ready for passage.
Preparing mTeSR1 adapted hPSCs for cryopreservation
1. mTeSR1 adapted cells are cryopreserved in mFreSR medium (Stem Cell Technologies 05854).
2. Culture hPSCs in mTeSR1 until ready for passage.
3. Aspirate culture medium in biological safety cabinet.
4. Incubate hPSCs with prewarmed 1 mg/ml dispase (Stem Cell Technologies 07923) for 7 minutes
or until the edges of the colonies begin to curl.
5. Aspirate dispase.
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6. Rinse the cells three times with DMEM/F-12.
7. Add enough prewarmed mTeSR1 to cover cells.
8. With 5 ml plastic pipette, expel medium while scraping the plate to remove colonies. Be careful to
leave the colonies as big as possible. Do not triturate.
9. Transfer to 15 ml tube.
10. Centrifuge at 300 x g for 5 minutes.
11. Aspirate medium.
6

12. Resuspend in appropriate volume of mFreSR (1 ml per 10 cells or 1 ml per 35 mm dish).
13. Transfer cell 1 ml suspension to each cryopreservation vial (Greiner Bio-one Cry-S).
14. Label vial with cell type, passage number, date and initials.
15. Place vial in Nalgene Cryo-1 (5100-0001)filled with isopropyl alcohol (Sigma Aldrich I9030)
16. Place in -80 °C for 24 hours.
17. Place in liquid nitrogen storage.
Passaging mTeSR1 adapted hPSCs
1. The cells receive medium changes every day and are passaged every 3-4 days.
2. Split ratios were 1:4 or 1:5.
3. Coat new dishes with Matrigel using protocol “Coating tissue Culture Treated Plates With
Matrigel”.
4. Inspect colonies for signs of differentiation before passaging, and colonies that appear
differentiated should be removed by scraping with a plastic pipette tip.
5. Aspirate cell culture medium.
6. Incubate cells in 1 mg/ml dispase (Stem Cell Technologies) for 7 minutes or until the edges of the
colonies began to curl.
7. Aspirate dispase and rinse three times in DMEM/F-12
8. Add enough mTESR1 to cover the cells.
9. Use a glass 5 ml pipette to scrape the colonies off the surface of the dish.
10. Transfer cell aggregates to a 15 ml centrifuge tube.
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11. The colonies were broken into smaller pieces by pipetting up and down several times with a 5 ml
glass pipette.
12. Resuspend in the appropriate volume of medium.
13. Aspirate Matrigel/DMEM/F-12 from new dishes.
14. Transfer cell aggregates to their new Matrigel coated dishes.
15. Inspect the dishes by light microscope to ensure that the aggregates are the right size (~50-60
μm in diameter).
16. Place in a 37 °C incubator with 5% CO2.
17. Medium should be changed every day.
Knockout serum replacement containing embryoid body medium
Using aseptic technique, combine the following ingredients:

For 50 ml Medium
DMEM/F-12

39 ml

Hyclone

SH30261.01

Knockout serum replacement

10 ml

β-mercaptoethanol

500 μl

Invitrogen
EMD Millipore

10828-028
ES-007-E

Non-Essential Amino Acids

500 μl

Hyclone

SH30238.01

Mix well and store at 4 °C for up to 2 weeks.
L-Ascorbic acid
1. Dissolve 75 mg of L-ascorbic acid in 25 ml of water. Concentration of stock solution is 3 mg/ml.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Store at -20 C in 1 ml aliquots.
Na Selenite
1. Dissolve 7 mg of Na Selenite in 100 ml of water. Concentration of the stock solution is .07 mg/ml.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Store at -20 C in 1 ml aliquots.
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Thiamine HCl
1. Dissolve 50 mg Thiamine HCl acid in 25 ml of water. Concentration of stock solution is 2 mg/ml.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Store at -20 C in 1 ml aliquots.
Bovine Serum Albumin
1. Dissolve 1.45 g BSA in 14.5 ml water. Gently shake to dissolve. Concentration of stock solution
is 100 mg/ml.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Use immediately to prepare SF-EB medium.
Glutathione (reduced)
1. Dissolve 50 mg Glutathione in 25 ml of water. Concentration of stock solution is 2 mg/ml.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Store at -20 C in 1 ml aliquots.
Sodium chloride
1. Dissolve 3 g Sodium Chloride in 8.5 ml of water.
2. Bring total volume to 10 ml.
3. Sterilize with 0.2 um filter (Corning 431224)
4. Store at 4° C.
Sodium Bicarbonate
1. Dissolve 900 mg sodium bicarbonate in 10 ml water.
2. Sterilize with 0.2 um filter (Corning 431224)
3. Store at 4° C.
100 ml of mTeSR1 compatible SF-EB medium
1. Thaw frozen stock solutions.
2. Combine ingredients in the following amounts:
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Ingredient

Volume (ml)

DMEM F-12

79.34824956

Thiamine HCl

0.3

Glutathione reduced

0.105

Lipids

0.194150441

Trace B

0.2

Trace C

0.1

NEAA

1

Betamercaptoethanol

1

Bovine Serum Albumin

12.96

Insulin Transferrin Selenium solution

2

L-Ascorbic Acid

1.6666

Na selenite

0.022

Sodium Bicarbonate

0.604

NaCl

0.63

L-Glutamine or Glutamax

0.5

Mix thoroughly.
3. If necessary, bring pH to 7.3 and filter.
4. Store at 4 °C.
SF-EB Formation Protocol
1. When hPSC dishes are 70-90% confluent and maintained undifferentiated (cells should not be
differentiated at this stage), incubate the cells at 37 °C with 0.5 mg/ml dispase in DMEM/F12 for
30-40 minutes, or until the colonies began to lift off of the plate.
2. Gently shake the plate to dislodge the colonies.
3. Do not aspirate. Tip the dish and dislodge any remaining adherent colonies off with DMEM/F12.
4. Transfer cell colony suspension to a 15 ml centrifuge tube.
5. Allow cell aggregates to sediment by gravity, and gently aspirate the dispase solution.
6. Rinse aggregates three more times in DMEM/F12.
7. Resuspend aggregates in EB medium.
8. Seed aggregates into six well ultra-low attachment plates (Costar 3471)

51

9. If the EBs are formed from a 100 mm dish, then resuspend in 12 ml SF-EB medium and add 2 ml
per well of the 6 well plate.
10. Add 1 additional ml of EB medium to each well to bring the final volume to 3 ml.
11. Place in a 37 °C incubator with 5% CO2.
12. Medium is refreshed on day 1 post EB formation and then every other day after that.
a. Tip the plate toward you.
b. Aspirate 2 ml medium without disturbing EBs.
c.

Add 2 ml of prewarmed EB medium.

RNA Extraction Protocol For hPSC Derived Embryoid Bodies (EBs)
Specialized Materials:
Qiagen RNeasy Mini kit (Cat # 74134)
Proteinase K (20 mg/ml) (Ambion Cat #AM2546)
Omni TH tissue homogenizer.
Qiagen RNase free DNase set (79254)
Protocol:
1. Transfer suspension EBs to a 15 ml tube and allow them to sink to the bottom of the tube by
gravity.
2. Gently aspirate the EB medium out of the plates.
3. Rinse the EBs with 1 ml PBS and transfer to a 1.5 ml eppendorf tube.
4. Centrifuge the tube for a few seconds.
5. Gently aspirate the PBS.
6. At this point the EB pellet can be stored in a –80 °C freezer until use.
7. Before beginning RNA extraction, add 10 μl of 2-mercaptoethanol to every 1 ml of RLT buffer you
intend to use.
8. Add 300 μl RLT buffer to the EB pellet.
9. Gently vortex the sample to facilitate lysis.
10. Lyse and homogenize the sample using an Omni TH tissue homogenizer.
11. Add 590 μl of RNAse free water to the sample.
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12. Add 10 μl of Proteinase K (20 mg/ml solution) and mix.
13. Incubate the mixture in a 55 °C water bath for 10 minutes.
14. Centrifuge at room temperature at 10,000 x g for 3 minutes. After centrifugation, there should be
a pellet of debris on the bottom of the tube.
15. Transfer the supernatant to a new tube, being careful not to disturb the pellet.
16. Add 450 μl of 100% ethanol to the lysate and mix.
17. Transfer 700 μl of lysate to an RNeasy spin column and centrifuge at 12,000 rpm for 15 seconds.
Discard the flow through.
18. Repeat step 17 in the same spin column until all the lysate is used.
19. Add 350 μl of RW1 buffer to the spin column and centrifuge for 15 seconds. Discard the flow
through.
20. In separate tube, mix 10μl DNase solution with 70 μl of RDD buffer.
21. Add 80 μl of solution from step 20 to the column.
22. Allow to sit at room temperature for 15 minutes.
23. Add 350 μl of RW1 buffer to the spin column and centrifuge for 15 seconds. Discard the flow
through.
24. Add 500 μl of RPE buffer to the spin column and centrifuge for 15 seconds. Discard the flow
through.
25. Add 500 μl of RPE buffer to the spin column and centrifuge for 2 minutes. Discard the flow
through.
26. Transfer the spin column to a new collection tube and centrifuge for 1 minute in order to dry the
column.
27. Transfer the spin column to a new 1.5 ml eppendorf tube. Add 30-50 μl of RNAse free water
directly to the column and centrifuge for 1 minute to elute the RNA.
28. Label the tube and store at – 20 C for downstream processes.
Reverse Transcription
1. Reverse transcription was carried out using Applied Biosystems High Capacity cDNA reverse
transcription kit (Catalog # 4368814) using manufacturer’s protocol.
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2.

Reaction was set up as follows in 1.5 ml eppendorf tubes:
a.

2 μl 10x RT Buffer.

b. 0.8 μl 25x dNTP mix.
c.

2 μl 10x RT random primers.

d. 1 μl Multiscribe reverse transcriptase.
e. 4.2 μl RNase free water.
f.

2 μg of RNA in Rnase free water to a total reaction volume of 20 μl.

3. Mix well.
4. allow reaction to take place at 25 °C for 10 minutes.
5. 37°C for 2 hours.
6. 85 °C for 5 minutes.
7. The cDNA was stored at - 20 °C.
qRT-PCR Primer design
1. Sequence for gene of interest is copied from the NCBI database.
2. Using MIT’s online primer design tool Frodo (http://frodo.wi.mit.edu/):
a. Paste sequence into user interface.
b. Product size range set between 100-200 base pairs.
c.

Set concentration of monovalent cations to 60 mM.

d. Click “Pick Primers”.
3. Check candidate primers for specificity in NCBI database:
a. On gene of interest mRNA page, select “Pick Primers”.
b. Paste candidate primers into appropriate fields.
c.

Click “Get Primers”.

d. Repeat process until a primer with high specificity is found.
Primer reconstitution
1. Primers are briefly centrifuged (a few seconds).
2. Primers are reconstituted to 50 mM based on product sheet of primer.
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3. All primers purchased from Eurofins.
4. Primers are further diluted to 6.25 mM in 1.5 ml eppendorf tubes.
qRT-PCR protocol
1. qRT-PCR carried out using the Power SYBR Green PCR Master Mix (Applied Biosystems
4368708).
2. Individual reaction mix consists of:
a. 12.5 μl SYBR master mix.
b. 2 μl forward primer stock solution.
c.

2 μl reverse primer stock solution.

d. 2.5 μl cDNA template (40 ng or 100 ng reactions)
e. Water to 25 μl.
3. All components kept on ice when not in use.
4. The reactions were carried out on an Eppendorf realplex4.
5.

The temperature ramping speed of the instrument was adjusted to 9600 emulation mode.
a. Denaturation step set to 13%.
b. Annealing step set to 30%.

6. The cycle settings were as follows:
a. 10 minutes 95 ° C Polymerase activation step
b. 15 seconds 95 ° C Denaturation step.
c.

30 seconds 60 ° C Annealing step

d. 30 seconds 72 ° C Extension step
e. b-d are repeated 40x.
f.

Melting curve.

7. β-actin was selected as housekeeping gene.
8. In most cases, undifferentiated H9 hESCs used as calibrator.
9. Fold change calculations were performed using the ΔΔCt method.
a. ΔCt(sample)= CtGOI -Ctβ-actin
b. ΔCt(calibrator)= CtGOI -Ctβ-actin
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c.

ΔΔCt = ΔCt(sample) - ΔCt(calibrator)

d. Fold change = 2

- ΔΔCt

.

4% Paraformaldehyde
1. Weigh out 1.2 g of paraformaldehyde (Sigma Aldrich P6148)
2. Add 19 ml of water.
3. Heat to 60 °C.
4. Add 5 M NaOH 10 μl at a time until paraformaldehyde completely dissolves.
5. Add 3 ml of 10 x PBS.
6. Bring volume of solution to 30 ml with water.
7. Adjust pH to 7.2 with 5 M HCl.
8. Store at 4 °C for up to 1 week.
Sucrose solution
7.5% solution
1. Weigh out 2.25 g sucrose (Fluka 84097)
2. Dissolve in 30 ml 1x PBS (Cellgro 21-031-CV)
3. Store at 4 °C.
15% solution
1. Weigh out 4.5 g sucrose (Fluka 84097)
2. Dissolve in 30 ml 1x PBS (Cellgro 21-031-CV).
3. Store at 4 °C.
Immunostaining - fixing
1. Transfer suspension EBs to a 15 ml tube and allow them to sink to the bottom of the tube by
gravity.
2. Gently aspirate the EB medium.
3. Rinse the EBs with 1 ml PBS and transfer to a 24 well plate.
4. Gently aspirate the PBS.
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5. Fix EBs is 4% paraformaldehyde for 20 minutes
6. Aspirate paraformaldehyde without disturbing EBs.
7. Rinse with PBS and aspirate.
8. Incubate EBs with 7.5 % sucrose solution for 3 hours at room temperature.
9. Carefully aspirate solution.
10. Incubate with 15% sucrose solution overnight at 4°C.
11. Carefully transfer EBs to a 15x15x5 mm vinyl freezing medium mold (Tissue Tek ).
12. Aspirate sucrose solution.
13. Add enough freezing medium to fill the mold (Triangle Biomedical Sciences TFM-5).
14. Molds are frozen at -20 ºC and then either stored at – 80 ºC or used immediately for
cryosectioning.

Immunostaining – Cryosectioning
1. Triangle Biomedical Systems Minotome Plus is set to – 20 °C.
2. If the samples had been stored at – 80 °C, place them in the microtome to allow them to come up
to temperature. Sample will be brittle if sections are made just after removing from – 80 °C.
3. To make 8 μm sections, set the index post to 4.
4. Place a small amount of tissue freezing medium on the specimen holder.
5. Mount the sample on the specimen holder, pushing the sample out of the sample mold.
6. Let sit in – 20 °C until sample adheres to the sample holder.
7. Mount the sample to the specimen orientation assembly.
8. Mount a disposable blade (TBS Shur-Sharp) to the knife assembly.
9. Advance the specimen to a point where the surface of the specimen is almost touching the blade.
10. Orient the specimen to the blade such that the blade will cut across the specimen evenly.
11. Take your time here. The EBs tend to settle near the bottom of the sample mold before the
tissue freezing medium freezes, and this means that when the sample is mounted to the sample
holder, many of the EBs will be sitting near the top of the frozen sample. Most of the really good
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sections that you can hope to get will be made in the first few cuts, so it is important to make sure
the sample and the blade are properly oriented from the start.
12. Also adjust the anti-roll plate so that it is almost even with the tip of the blade.
13. Start making cuts. If everything is set up correctly, the section should come out underneath the
antiroll plate in one thin sheet. If this is not working, sometimes it helps to have the anti-roll plate
raised when you begin the cut and then press the anti-roll plate down into position as you are
making the cut. The timing of this move is a little tricky at first, but it gets much easier with just a
little practice.
14. Transfer the sections to poly-L-lysine coated slides (Electron Microscopy Sciences #63410).
15. Check the slide under a light microscope to make sure you are catching the EBs.
16. Allow slides to sit at room temperature for 30 minutes and then store them at – 80 ° C until ready
for staining.
0.5% Saponin
1. Combine 100 mg Saponin (Sigma 47036) with 20 ml water in 50 ml tube.
2. Gently vortex to mix. Keep settings low, because the solution will foam if vortexed too strongly.
Immunostaining – Immunofluorescence
1. Slides were removed from – 80 °C and allowed to air dry for 30 minutes.
2. Incubate samples in 0.5% Saponin in PBS for 10 minutes to permeablize the cells.
3. Rinse slides 3x with PBS.
4. Block samples with 1% BSA (Fisher Scientific BP1600-100) in PBST for 30 minutes.
5. Dilute antibody in 1% BSA in PBST.
6. Incubate sample in antibody for 1 hour at room temperature.
7. Decant solution and wash 3x with PBS, 5 minutes each wash.
8. Dilute secondary antibodies in 1% BSA in PBS.
9. Incubate secondary antibodies for 1 hour in the dark.
10. Decant solution and rinse 3x with PBS in the dark.
11. Stain nuclei with DAPI 1:100 dilution in PBS for 1 minute in the dark.
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12. Rinse with PBS.
13. Visualize with Olympus IX71 Fluorescent Microscope and Slide Book software.
RIPA Buffer
1. 150 mM Sodium Chloride (Acros 327300010)
2. 1% TritonX-100 (Acros 327371000)
3. 0.5% sodium deoxycholate (Sigma Aldrich D6750)
4. 0.1% sodium dodecyl sulphate (SDS) (VWR VW1495-04)
5. 50 mM Tris (Cal Biochem 9210)
Tris-Cl/SDS (pH6.8)
1. 40 ml H2O
2. 1.51 g Tris-Base (Cal Biochem 9210)
3. 0.1 g SDS (VWR VW1495-04)
4. Adjust pH to 6.8.
Loading Buffer
1. 7 ml 4x Tris-Cl/SDS (pH 6.8)
2. 3 ml glycerol (Fisher BP229-1)
3. 1 g SDS (VWR VW1495-04)
4. 0.93 g DTT (Gold Biotechnology DTT10)
5. Bromophenol blue (Sigma Aldrich B0126)

Preparation of PAGE Gel
1. 10% separating gel (0.75mm)
a. 1.9 ml dH2O
b. 1.3 ml 1.5 M Tris (pH 8.8)
c.

1.7 ml 30% acrylamide (Shelton Scientific IB70022)

d. 50 μl 10% SDS (VWR VW1495-04)
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e. 50 μl 10% APS (Sigma Aldrich A3678)
f.

2 μl TEMED (Amersham Biosciences 17-1312-01)

2. 5% stacking gel
a. 1.4 ml dH2O
b. 250 μl 1.0 M Tris (pH 6.8)
c.

330 μl 30% acrylamide (Shelton Scientific IB70022)

d. 20 μl 10% SDS (VWR VW1495-04)
e. 20 μl 10% APS (Sigma Aldrich A3678)
f.

2 μl TEMED (Amersham Biosciences 17-1312-01)

SDS Page buffer
1. 100 ml 10x Tris/Glycine/SDS buffer (BIO-RAD 161-0732)
2. 900 ml nanopure water
Transfer Buffer
1. 100 ml 10x Tris/Glycine buffer (BIO-RAD 161-0734)
2. 200 ml methanol (Fisher Scientific BP1105-4)
3. 700 ml nanopure water
Western Blot
1. Transfer suspension EBs to a 15 ml tube and allow them to sink to the bottom of the tube by
gravity.
2. Gently aspirate the EB medium.
3. Rinse the EBs with 1 ml PBS and transfer to a 1.5 ml eppendorf tube.
4. Centrifuge the tube for a few seconds.
5. Gently aspirate the PBS.
6. Add 300 μl of cold RIPA lysis buffer with 1 mM PMSF (Pierce 36978) to tube.
7. Homogenize the sample using Omni TH tissue homogenizer.
8. Maintain agitation for 30 minutes at 4 °C.
9. Centrifuge at 4 °C for 15 minutes.
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10. Remove supernatant from tube and place in a new eppendorf tube.
11. Combine 1:1 ratio of loading buffer with sample.
12. Heat mixture at 95 °C for 5 minutes.
13. Briefly vortex sample.
14. Load 20 μl sample into each lane of gel along with molecular weight marker Pageruler Plus
Prestained Protein Ladder (Thermo Scientific 26619).
15. Run gel on BIO-RAD Power Pac Universal 120 minutes at 90 V.
16. Wet transfer is performed using a nitrocellulose membrane (BIO-RAD 1101093) for 60 minutes at
150 V.
17. Block membrane in 5% milk (BIO RAD 170-6404) for 1 hour at 25 ° C.
18. Anti-Beta Catenin Rabbit monoclonal antibody (Abcam ab32572) is diluted 1:5000 in 5% milk.
19. Anti-Beta actin antibody (Sigma Aldrich A3854) is diluted 1:30000 in 5% milk.
20. Incubate membrane with primary antibody overnight at 4 ° C.
21. Rinse 3x in PBST, 5 minutes per wash.
22. Incubate membrane with secondary antibody goat polyclonal anti rabbit conjugated to HRP
(Rockland 611-1302) for 1 hour at room temperature with agitation.
23. Rinse 3x in PBST, 5 minutes per wash.
24. Develop using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific 34077).
a. Mix substrate solutions ina 1:1 ratio
b. Incubate with membrane for 5 minutes in dark.
c.

Drain excess solution.

d. Cover blot with clear plastic wrap.
25. Take images with BIO RAD Universal Hood II.
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